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In mythology, a quest is a journey towards a goal, frequently serving as a symbol. By the quest, the 
hero aims to obtain an object, something or someone that fulfills a lack in her life. Obtaining this 
object requires great exertion on the part of the hero and the overcoming of many obstacles. 
In narratology, the monomythe (or the hero's journey) is the common template of a broad category 
of tales that involve a hero who goes on an adventure, in a decisive crisis wins a victory, and then 
comes home changed or transformed. The hero’s story is described in different stages. 
The Departure 
The hero lives in the ordinary world and receives a call to go on an adventure. The hero is reluctant 
to follow the call, but is helped by a mentor figure. 
The Initiation 
The hero traverses the threshold to the unknown or "special world", where she faces tasks or trials, 
either alone or with the assistance of helpers. The hero eventually reaches "the innermost cave" or 
the central crisis of her adventure. Here she must undergo "the ordeal" where she overcomes the 
main obstacle or enemy, undergoing "apotheosis" and gaining her reward. 
The Return 
The hero again traverses the threshold between the worlds, returning to the ordinary world with the 
treasure she gained, which she may now use for the benefit of her fellow man. The hero herself is 
transformed by the adventure and gains wisdom or spiritual power over both worlds. 
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An American endocrinologist, Henry Turner (1892-1970), described in 1938 “a syndrome of 
infantilism, congenital webbed neck, and cubitus valgus” [154]. Although we currently know that the 
pathology is much more complex than described in his first publication, this clinical entity entered 
history as Turner syndrome (TS). 
In the last decades, the knowledge about TS increased dramatically. In this introduction, the 
incidence and the complexity of the genetic and clinical picture of Turner syndrome will be 
described with focus on its cardiovascular aspects. 
 
I.1 Turner genotype and phenotype 
I.1.1 Turner genotype 
TS is a chromosomal disorder occurring only in females. It is caused by a partial or a complete 
absence of an X chromosome. This may occur within the presence of a structurally abnormal X 
chromosome (isochromosome or ring chromosome) or the presence of Y-chromosome material. 
The genotype of TS is therefore very diverse complicating research in this patient group. 
Classification is often presented in 4 major groups presented in table 1. 
Table 1: Turner genotype 
Monosomy 45,X  
Isochromosome 46,X,i(X)  
Deletion 46,X,del(X)  
Mosaic forms consisting of 45X with another cell line 46,XX 
 46,X,i(Xq) 
 46,X,del(X) 




Data on the prevalence of the different genotypes in live born girls are diverse and difficult to 
compare due to the different categorisations used. In all datasets, the largest subgroup consists of 
monosomy 45,X found in 36 to 45% of TS patients [106, 141, 149]. Another important but highly 
heterogeneous genotype subgroup is formed by the mosaic forms that express both a normal 46,XX 
and an abnormal cell line (table 1). The degree of mosaicism is expressed as the number of normal 
46,XX to the number of abnormal cells (i.e. 46,XX [45]/45,X [55]). The relation between both cell 
lines in patients is not constant and varies according to the number of meioses counted, the tissue 
studied and with age [38]. In nature, a true monosomy is not compatible with life and all 45,X 
individuals with monosomy are probably low graded mosaics [74]. For the purpose of this thesis 
however, monosomy 45,X remains valid as a subgroup.  
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I.1.2 Turner phenotype 
Table 2: Turner phenotype  
System Abnormality 
Dismorphic features Webbed neck 
 Shield chest with widely spaced nipples 
Gonadal No pubertal development 
 Infertility 
 Chronic estrogen deficiency 
Endocrine Short stature 
 Hashimoto thyroiditis and hypothyreosis 
 Diabetes mellitus type 1 and 2 
 Dyslipidemia 
 Decreased bone mineral content 
Cardiovascular Structural congenital heart disease (left sided) 
 Progressive dilation of the ascending aorta 
 Hypertension 
 ECG abnormalities 
Gastrointestinal and hepatic Celiac disease 
 Elevated hepatic enzymes 
 Inflammatory bowel disease 
Renal Horseshoe kidney 
 Abnormal positioning or duplication 
Skeletal Cubitus valgus 
 Scoliosis 
 Madelung deformation 
 Short 4th metacarpal 
 Genu varu 
Nose, ear, throat Distortion of the Eustachian tube 
 Neurosensorial hearing loss 
 Micrognathia 
 High arched palatum 




Dermatological Increased skin ridge count 
 Lymphedema  
 Multiple pigmented naevi 
 Nail hypoplasia 
 Vitiligo 
 Alopecia 
 Low posterior hair line 
Neurological Emotional immaturity 
 Specific learning problems 
 Poor visuospatial organisation 
 ADHD  
 Autism and mental problems 
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The most distinctive clinical features of Turner syndrome are small stature and premature ovarian 
failure but patients also present a broad spectrum of other diseases with a major impact on 
morbidity and mortality. 
All systems that can be affected are listed in table 2. Although the phenotype can vary highly in 
severity, most TS patients develop problems in several systems and benefit from a multidisciplinary 
follow-up. 
 
I.1.3 Association between genotype and phenotype in Turner syndrome 
It is not defined yet which chromosomal regions and genes account for the physical characteristics 
of TS, but there seems to be some association between the genotype and phenotype in TS [149]. 
Girls with monosomy 45X are more likely to present with congenital lymphedema. TS patients with 
mosaic 45,X/46,XX have a higher chance for normal menarche and fertility while those with 
45,X/46,XX/47,XXX tend to have a taller final height. The presence of an isochromosome X 
increases the risk for hypothyroidism and inflammatory bowel disease while a marker or ring 
chromosome is more likely to be associated with mental retardation. TS girls with a 46,X/46,XY 
genotype are at an increased risk for germ cell tumours [28]. 
One of the subgroups of the TS genotype is formed by sex chromosome mosaicism (45,X/46,XY 
and variants). Apart from females TS patients, this genotype is also found in apparently normal 
males presenting at infertility clinics, in boys consulting for short stature or in neonates born with 
genital ambiguity [22, 151]. Some males patients with a mosaic 45,X/46,XY show stigmata typically 
associated with TS like short stature, renal pathology and coarctation [151]. 
Some data suggest a correlation between the Turner genotype and the cardiac phenotype. The 
most severe cardiac phenotypes are found in TS patients with a monosomy 45,X. They more 
frequently have congenital heart disease [109, 135, 136, 140] and develop more severe aortic 
dilation [135] than those with other genotypes. The high prevalence of BAV and coarctation in TS 
patients with an Xp deletion, suggests that haploinsufficiency for genes that are located on Xp 
contribute to an abnormal aortic valve and aortic arch development [8]. This phenomenon could 
also explain the increased incidence of BAV and aortic pathology in males with 45,X/46,XY. 
Left sided heart defects like bicuspid aortic valve and coarctation are more frequently found in TS 
patients with a webbed neck compared to those without [72, 94, 140]. The webbed neck is a 
remnant of the central fetal lymphedema that is often noted prenatally in TS foetuses. It can present 
as a severe cystic hygroma or as an increased nuchal translucency. There are several hypotheses 
to explain this association between abnormal fetal lymphedema and the congenital heart defects 
found in TS. Clark hypothesises that centrally localized distended lymphatic sacs compress the 
developing aortic root, resulting in specific left-sided defects, including hypoplastic left heart, BAV, 
and coarctation due to low flow, and specific right-sided defects such as persistent left superior 
caval vein, anomalous pulmonary venous return, and dilated right atrium, due to back pressure from 
obstruction to forward flow [26]. In favour for this hypothesis is the well known association between 
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fetal increased nuchal translucency and congenital heart defects that is also found in non-TS 
foetuses [75]. An alternative explanation for the association between neck webbing and BAV in TS 
could be the haploinsufficiency for an X-chromosome gene that causes central fetal lymphedema 
and aortic heart defects independent of each other [140]. 
Some X-linked genes have been put forward as being possibly involved. Vascular endothelial 
growth factor (VEGF) is a specific growth factor for endothelium that also plays a role in the 
signalling involved in embryonic endocardial-to-mesenchymal transformation of the endocardial 
cushions. Overexpression of VEGF during fetal life is associated with fetal hydrops and with the 
development of congenital heart defects [16]. 
 
I.1.4 Timing of diagnosis of Turner syndrome 
The phenotype of TS patients is highly variable and may change over time as some diseases only 
appear later in life. In many patients, the diagnosis of TS is delayed until adult age. The age at the 
diagnosis of TS depends on the phenotype and the clinical presentation. 
Prenatal diagnosis of TS is mostly made “accidently” after amniocentesis for increased nuchal 
translucency, abnormal triple testing or advanced maternal age. Prenatal genetic testing can also 
be performed after the prenatal detection of a congenital heart defect (CHD). In case of an 
incidental finding of mosaic 45,X/46,XX or 46,X/46,XY without abnormalities on prenatal ultrasound, 
the initial phenotype at birth is often normal [149]. 
One fifth to one third of TS girls receive their diagnosis in the neonatal period because of puffy 
hands and feet, webbed neck or the presence of left sided CHD. Another third is diagnosed in 
childhood on investigation for short stature. Most other patients present in adolescence or adulthood 
because of absent or arrested puberty or infertility. 
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I.2 Incidence of Turner syndrome 
I.2.1 Incidence of Turner syndrome in live born girls 
Turner syndrome is a rare disease with an estimated incidence of 1/2000 [116] to 1/5000 [77, 96] 
live born girls. This might however be an underestimation as the phenotype can be mild and 
patients may remain clinically undiagnosed. Moreover, older genetic techniques were insufficient to 
detect low grade mosaicism categorising some TS patients as “normal 46,XX”. 
 
I.2.2 Incidence of Turner syndrome in the prenatal setting 
Data on prenatal genetic testing in a large non-selected population are lacking and the exact 
incidence of TS in early fetal life remains currently unknown. The incidence in foetuses is much 
higher than in the live born population as only a very small proportion of all foetuses with TS is born 
alive. Studies in foetuses with early spontaneous fetal death show a monosomy 45X in 2% of the 
cases [53]. In pregnancies that were terminated because of severely increased nuchal translucency 
or hygroma colli, 1% of the foetuses had TS [40]. Based on this data, Hook et al. calculated that 1 to 
1.5% of all clinically recognised pregnancies starts as a monosomy 45X but 99% of the foetuses 
does not survive [73]. 
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I.3 Cardiovascular pathology in Turner syndrome 
Cardiovascular pathology is highly prevalent in TS and adds significantly to the morbidity and 
mortality of the syndrome. In this section, the cardiovascular pathology related to TS is described 
using the most common classification. Congenital structural heart defects, dilation and dissection of 
the aorta as part of a generalised vasculopathy, hypertension and ECG abnormalities and 
sympathic dysfunction are discussed and a comparison is made between TS and the general 
population. 
 As described further in this chapter, CHD, hypertension and aortic dilation contribute to the risk of 
aortic dissection. Timely diagnosis, treatment and follow up of these pathologies help to reduce the 
occurrence of this often lethal complication. The following section therefore describes extensively 
their clinical presentation and the current treatment strategies. 
 
I.3.1 Congenital structural heart defects 
Structural congenital heart defects (CHD) are frequent in TS and mainly involve the left side of the 
heart. In table 3, the prevalence of the most frequent abnormalities in TS are listed and compared to 
data of the general population [6, 39, 48, 55, 72, 81, 94, 109, 136].  
 
Table 3: prevalence of CHD in TS compared to the general population 
Heart defect TS (%) General population (%) 
Bicuspid aortic valve 14 – 40 1 - 2 
Coarctation of the aorta 4 – 15 0.04 
Elongated transverse aortic arch 31 – 49 Non existing 
Bovine arch 6 – 29 13 
Aberrant right subclavian artery 6 – 8 0.5 – 2.5 
Persistent left superior caval vein 8 – 13 0.3 – 0.5 
Partial anomalous pulmonary venous connection 4 – 16 unknown 
Hypoplastic left heart syndrome 4 – 5 0.0002 – 0.0003 
 
The reported prevalence of structural heart disease in literature is highly variable and partially 
depends on the imaging technique used (MRI or ultrasound). Echo windows in TS can be very poor 
due to obesity and an increased anteroposterior diameter of the thorax. MRI can overcome these 
difficulties, thus leading to a higher reported prevalence of bicuspid aortic valve, aortic coarctation 
and partial anomalous pulmonary venous connection. 
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I.3.1.1 Bicuspid aortic valve 
Definition 
Bicuspid aortic valves (BAV) can either have 2 cusps (structurally bicuspid) or 3 cusps of which 2 
are completely or partially fused (functionally bicuspid). When the right and left coronary cusp are 
fused the valve has an anterior-posterior configuration on transthoracic echocardiography. When 
the non-coronary cusp is fused with the left or right coronary cusp, the BAV has a left-right 
configuration [32] (figure 1). 
In TS, only 1 in 3 BAV is structurally bicuspid. The others are functionally bicuspid. In the majority of 
cases BAV have an anterior-posterior configuration on transthoracic echocardiography [140]. 
 
 
Figure 1: two-dimensional cross-section of the aortic valve on echocardiography with a schematic 
representation of the various abnormal aortic valve morphologies. L=left; R=right [32]. 
 
Prevalence in TS 
The reported prevalence of BAV in TS is high, ranging from 14 to 40% [39, 48, 55, 81, 94, 109, 
136]. The highest numbers are found is studies were imaging was performed using MRI [81, 109]. 
Clinical significance 
BAV is highly prevalent in TS but clinically important dysfunction of the aortic valve is rare [109, 124, 
140]. Severe insufficiency is found in 4 to 15% of TS patients [124, 140] and although TS patients 
show an increased peak velocity across the aortic valve, moderate to severe stenosis is only found 
in 2% [124, 140] 
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BAV is often associated with structural abnormalities of the aorta such as dilation of the aortic sinus, 
sinotubular junction and ascending aorta (independent of the presence of aortic valve stenosis) (25 
- 46%) [71, 109, 140], coarctation of the aorta (22%) [8] and elongated transverse arch (50%) [109]. 
Treatment 
A BAV only needs treatment when its is dysfunctional. In general, the therapeutic options are similar 
to the aortic valve pathology in other patient groups. When the aortic valve is severely stenotic but 
without significant insufficiency, the valve can be ballooned percutaneously. If there is a clinically 
important valvular insufficiency, surgical treatment is required. When the aortic valve has a 
reasonable size and is not severely dysplastic, conservative valvuloplasty is preferred. In TS 
patients with a concomitant dilation of the aortic sinus, the root is replaced by a vascular graft with 
re-implantation of the coronary arteries (David procedure). If the aortic valve is too dysplastic to 
repair, surgical replacement is necessary. In adults, replacement of the abnormal aortic valve with a 
mechanical valve is an option. If there is an associated dilation of the aortic root and the ascending 
aorta, the aortic valve, root and ascending aorta are replaced with a composite graft with re-
implantation of the coronary arteries (Bentall procedure). The use of mechanical valves and 
vascular graft interposition is avoided in children. In this young age group, the diseased aortic valve 
is replaced with the patient’s own pulmonary valve and a pulmonary allograft is used to replace the 
patients’ pulmonary valve (Ross procedure). 
Comparison with the general population 
In the general population, BAV is found in 1 to 2% and is more prevalent in males than in females. 
Fusion of the right-coronary and the left-coronary leaflet is the most common type (59-70%), both in 
isolated BAV and in BAV associated with congenital heart disease. Fusion of the right-coronary and 
non-coronary cusp is found in 28 - 37% while fusion of the left-coronary and non-coronary cusp is 
rare (1-4%) [24, 46]. 
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I.3.1.2 Coarctation of the aorta 
Definition 
Coarctation of the aorta is a stenosis of the descending aorta, which is typically located at the 
insertion of the arterial duct distal to the left subclavian artery (figure 2). 
Prevalence in TS 
The reported prevalence of aortic coarctation in TS ranges between 4 and 15% [39, 48, 55, 72, 81, 
94, 136]. The highest numbers are found in studies using the MRI technique [72, 81, 109]. 
 
 
Figure 2: coarctation in an 11 year old TS girl (MRI reconstruction image) 
 
Clinical significance 
The clinical significance of coarctation depends on the severity of the stenosis. If the coarctation is 
tight, patients present in the first days of life with severe cardiac decompensation after closure of the 
arterial duct (duct dependent circulation) and medical treatment is an emergency. Less severe 
stenosis often remains undetected until later in life. Adolescents and young adults present with 
upper limb hypertension and severe headache. In adult TS patients, coarctation can be an 
incidental finding on routine MRI [48, 81]. 
Coarctation of the aorta is frequently associated with BAV (21%) [8] and is often seen in association 
with elongation of the transverse arch (ETA) [72, 81, 109]. 
Even after successful treatment, patients with coarctation of the aorta remain at increased risk for 
hypertension later in life. The incidence of hypertension in non-TS patients treated for coarctation 
increases with age going from 1.36% in the paediatric group to 45.7% in patients above 30 years of 
age [164]. 
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Treatment 
Treatment of coarctation in TS is similar to that of coarctation in the general population and depends 
on the severity of the coarctation and the age at presentation. Severe neonatal coarctation is a 
medical urgency requiring prompt administration of IV prostaglandins to open the arterial duct and 
to relax the coarctation region followed by surgical resection of the narrowed aortic region. 
Significant coarctation that presents later in life can be treated either by balloon dilation, 
percutaneous stenting [167] or surgical resection. Surgical treatment in TS more often requires the 
more complex subclavian flap technique (instead of the straight forward end-to-end anastomosis), 
but long term results are similar to those obtained in non-TS patients [31]. 
Comparison with the general population 
In the general population, the reported prevalence of aortic coarctation is 4.4/10 000. 
 
I.3.1.3 Other structural abnormalities of the aortic arch 
Definition 
Apart from aortic coarctation, the aorta of TS patient can show other structural abnormalities: 
Elongation of the transverse arch (ETA): combination of late takeoff of the left subclavian artery 
behind the trachea and a box shaped appearance of the aortic arch with an acute angle along 
the lesser curvature of the aortic isthmus (figure 3). 
Bovine arch: common origin of the brachiocephalic trunk and the left common carotid artery. 
Right arteria lusoria: abnormal origin of the right subclavian artery that does not arise from the 
brachiocephalic trunk but originates distal to the left subclavian artery and courses to the right 
behind the oesophagus. 
 
 
Figure 3:  in the left panel elongation of the transverse arch (ETA) compared to a normal 
aortic arch in the right panel 
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Prevalence in TS 
All reported prevalences are derived from MRI studies [72, 81, 109]: 
ETA: 31 to 49% 
Bovine arch: 6 to 29% 
Right arteria lusoria: 6 to 8% 
Clinical significance 
Structural abnormalities of the aorta have little clinical significance. An aberrant right subclavian 
artery is usually asymptomatic, but can cause dysphagia and dyspnea or chronic coughing in some 
patients [112]. ETA is isolated in 50% of the cases but can be associated with other structural heart 
defects like coarctation of the aorta or BAV [72, 81, 109]. 
Comparison with the general population 
ETA is a typical finding in TS and is not described in the general population. The overall prevalence 
of bovine aortic arches in the general population is 13% (8% in Caucasians and 25% in individuals 
of African origin) [91]. A right arteria lusoria is reported in 0.5 to 2.5% [112]. 
 
I.3.1.4 Persistent left superior caval vein 
Definition 
A persistent left superior caval vein (LSVC) is a remnant vessel that is present as a counterpart of a 
normal right-sided superior caval vein in early embryological development and that normally 
disappears during fetal life. It drains venous blood to the right atrium through the coronary sinus. 
Prevalence in TS 
Although it is possible to visualize LVCS on ultrasound, most cases in TS are reported in MRI 
studies with a prevalence of 8 to 13% [72, 81]. 
Clinical significance 
In general, LSVC has no clinical significance and does not require medical treatment. In patients 
with TS, it is often associated with ETA or right arteria lusoria [72]. 
Comparison with the general population 
In the general population, LSVC is found in 0.3 to 0.5% [150]. 
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I.3.1.5 Partial anomalous pulmonary venous connection 
Definition 
In partial anomalous pulmonary venous connection (PAPVC) one or more pulmonary veins drain 
abnormally to the right instead of to the left atrium. 
Prevalence in TS 
PAPVU is reported in 4 to 16% of TS patients with higher numbers in studies with MRI compared to 
imaging by ultrasound [6, 72, 81, 101]. Abnormal drainage of the left pulmonary veins is the most 
common form in TS. 
Clinical significance 
The clinical significance of PAPVC depends on the number of abnormal veins and the amount of 
blood that drains to the right atrium. In most cases, PAPVC is an incidental finding without clinical 
repercussion. If several veins drain abnormally to the right atrium, patients exhibit signs of right 
sided volume overload with exercise intolerance as the major clinical complaint. If not recognised, it 
can eventually evolve towards pulmonary hypertension. 
Treatment 
The treatment of PAPVC is similar in TS compared to the general population. Surgical re-routing of 
the abnormal veins to the left atrium is considered when there are clinical or radiological signs of 
volume overload. 
Comparison with the general population 
There are no data on the prevalence of PAPVC in the general population. Abnormal drainage of the 
right sided pulmonary veins is 10 times more frequent than an abnormal drainage of the left sided 
pulmonary veins [2, 146]. The most common type is PAPVC to the superior caval vein (74%) of 
which 87% is associated with a sinus venosus atrial septum defect [2]. 
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I.3.1.6 Hypoplastic left heart syndrome 
Definition 
Hypoplastic left heart syndrome (HLHS) is the most extreme expression of left sided pathology. 
Although structural defects can vary, the overall characteristic is the severely underdevelopment of 
the left ventricle, the mitral valve and the aortic valve with no or insufficient forward flow through the 
aorta. HLHS is probably one of the reasons for the high proportion of spontaneous prenatal demise 
in TS foetuses. 
Prevalence in TS 
HLHS is found in 13.2% of TS cases that are detected prenatally. Most pregnancies end in a 
termination of pregnancy arte provocatus or in spontaneous intra uterine demise [147]. In TS babies 
who are born alive a prevalence of 4 to 5% is reported [31, 159]. 
Clinical significance 
If not detected prenatally, HLHS presents during the first days of life with severe shock when the 
arterial duct closes. Initial stabilisation requires urgent administration of IV prostaglandins. If not 
treated adequately, the situation quickly deteriorates towards death. 
Treatment 
The treatment of HLHS is similar in TS compared to the general population and consists of surgical 
palliation in 3 stages: 
- Norwood procedure in the neonatal period 
- bidirectional cavopulmonary anastomosis at the age of 3 to 6 months 
- total cavopulmonary anastomosis after the age of 3 years. 
Although the outcome after Norwood procedure improved dramatically over the last decade, this 
optimism does not apply to TS patients where the outcome remains very poor (mortality rate 75 to 
90%) compared to other children without TS [31, 95]. 
Comparison with the general population 
In the general population, HLHS is found in 2 to 3/10 000 live births with a male:female ratio of 
1.5/1. The reported prevalence is probably underestimated because of the indeterminate rate of 
spontaneous intra uterine demise and elective termination of pregnancy. 
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I.3.2 Dilation and dissection of the aorta and generalised vasculopathy 
I.3.2.1 Definition of normal aortic growth and evaluation of aortic diameters 
Aortic growth and aortic dimensions in children 
In children, the diameter of the aorta changes with age and growth. Therefore aortic dimensions are 
interpreted using z-scores that not only include the absolute aortic diameters but also the height and 
the weight (BSA) of the child. Until recently, the Sluysmans z-scores were the most frequently used 
in children [145]. 
              
                 
            
 
 
Measurements are made in systole from inner-to-inner wall. The BSA used in this formula is 
calculated according to Haycock [69] and takes into account body weight and height. 
 
Recently new z-scores were published that not only take include the weight and the height (BSA) 
but also the gender and the age of the patients [18]. 
 
                     
                                                 
      
 
 
Measurements are made in diastole from leading edge to leading edge. The BSA used in this 
formula is calculated according to Haycock [69] and takes into account body weight and height.. 
Aortic growth and aortic dimensions in adults 
In normal females the diameter of the aorta increases progressively with advancing age with an 
average of 0.9±0.4 mm/decade at the site of the aortic sinus and 1.2±0.5 mm/decade at the 
ascending aorta (BSA adjusted values) [18]. 
Prospective longitudinal data on the natural history of aortic growth in TS are scarce. There is only 
one study that repeated MRI imaging in a group of 102 adult TS women. This study showed an 
aortic growth rate in TS patients of 0.1-0.4 mm/year which exceeds the growth velocity of normal 
females [110]. The ascending aorta in TS women with a BAV grew faster that than in those with a 
TAV [110] . Also in non-TS patients, the presence of a BAV is associated with accelerated aortic 
growth with a mean increase in diameter of 0.77 mm/year [45]. 
  
The call to the adventure 
25 
I.3.2.2 Aortic dilation 
Definition 
Aortic aneurysm is an abnormal dilation or bulging of the aortic wall that involves the three layers of 
the vessel wall (figure 4). 
 
Figure 4:  schematic presentation of a normal aortic wall (left), aortic aneurysm (middle) and 
aortic dissection (right) 
Ascending aortas with a z-score ≥2 (above the 95
th
 percentile) are considered dilated. TS women 
are generally small and therefore it is now advised to use the aortic size index (ASI) that normalizes 
aortic diameters for BSA [98] for adult TS patients. ASI>20mm/m² corresponds to the 95
th
 percentile 
and ASI>25 mm/m² to the 99
th
 percentile. An ascending aorta/BSA >20mm/m² is considered dilated, 
>25mm/m² is considered a risk for dissection. Although these definitions are initially calculated 
based on an MRI images, they are also applied in clinical practice to echo derived measurements. 
Prevalence in TS 
In a large paediatric TS population, ascending aorta dilation (z-score ≥2) was seen in 30% and 
aortic root dilation (z-score ≥2) in 20% of TS girls. The proximal aortic diameters were even larger in 
the 26% of patients with a BAV [93]. Similar data (10% of patients with z-score of 1.96 and 20% of 
patients with z-score of 2) were found in an MRI study in a smaller group of TS girls [21]. 
In adulthood, enlarged aortic dimensions are frequently found at the aortic root and the ascending 
aorta. Although dilation is often associated with CHD, abnormally large aortic diameters are also 
found in adult TS patients without a heart defect. In relatively young TS patients without CHD or 
BAV, aortic root dilation is seen in 11% [135]; the prevalence is higher, up to 42%, in the total group 
[42, 81]. Ascending aortic dilation is reported in 8% of TS patients without CHD or BAV [135] and is 
higher (20 to 24%) in the total group of adult TS patients [71, 98, 109]. 
Clinical significance and treatment 
Aortic aneurysms are a major risk factor for aortic dissection. There are no prospective data on the 
surgical treatment of aortic aneurysms in TS and it currently remains unclear which aortic diameter 
urges prophylactic replacement. In clinical practice, treatment strategy is therefore based on 
theoretical assumptions. Aortic dilations with an ASI≥20 mm/m² require close follow-up and 
treatment of associated risk factors for dissection as hypertension or coarctation. In most centres, 
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an ASI ≥25mm/m² is considered an increased risk for aortic dissection and this diameter is used as 
a cut off for prophylactic aortic surgery [10, 19, 98, 156]. The role of medical treatment in the 
prevention of rapid aortic growth in TS remains unknown. There are no data to neither support nor 
reject the usefulness of medical treatment with betablockers or angiotensin converting enzyme in 
TS. 
 
I.3.2.3 Aortic dissection 
Definition 
Aortic dissection is a progressive tear in the aortic wall. The intima of the aorta tears and blood 
surges trough the tear, creating a new false lumen and dissecting the media from the adventitia 
(figure 4). Dissections that affect the thoracic and abdominal aorta are usually classified according 
to the Stanford or DeBakey classification (figure 5)[70]. The Stanford classification categorises 
dissections depending on whether the ascending aorta is involved or not. The Debakey 
classification categorises dissections based on the origin of the tear and the extend of the dissection 
(ascending aorta, descending aorta, or both). 
 
Figure 5: types of aortic dissection, classified according to Stanford and Debakey [117] 
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Incidence in TS 
There are little prospective data on aortic dissections in TS patients. The reported incidence of 
aortic dissection in TS patients is 36/100 000 patient years or 1,4% [61]. Dissection of the aorta 
occurs at the relative young mean age of 30 to 35 years with a range of 18 to 61 years [20, 61] but 
dissection is also reported in childhood [148]. In more than 2/3 of the cases, the aorta dissects at 
the level of the ascending aorta (Stanford type A dissection) while type B dissections are less 
common [19]. 
Clinical significance 
The clinical presentation of an acute aortic dissection is that of an acute thoracic syndrome. The 
symptoms are highly variable and can mimic those of other more common conditions like acute 
coronary syndrome or arrhythmia. Aortic dissection can present with congestive cardiac failure, 
syncope, acute stroke, acute myocardial  ,infarction, ischemic peripheral neuropathy, paraplegia 
and cardiac arrest or sudden death. Although not always present, most patient report severe pain in 
the chest, the back and/or the neck [144]. 
Preliminary data of the International Turner Syndrome Aortic Dissection Registry show that nearly 
all TS patients developed clinical symptoms of dissection, chest pain being the most common. Other 
frequently reported signs were neck or back pain, dyspnea, nausea or vomiting and dizziness. The 
initial presentation was sudden death in 9 of the 20 TS patients. Mortality after dissection was high 
with a survival rate of only 37% [19]. Symptoms of an acute aortic syndrome are often not 
recognised or ignored by the young TS patients which leads to a late or underdiagnosis and 
probably explains the high mortality of dissection in this group. 
Treatment 
Treatment of an acute Stanford type A dissection is a medical emergency since patients are at a 
high risk for life-threatening complications such as malperfusion syndrome, tamponade, massive 
aortic regurgitation or myocardial infarction. The type of the surgical procedure depends on the 
involvement of the aortic valve and root. Both are spared if possible. In case of an ascending aortic 
aneurysm without involvement of the aortic valve and root, the aneurysmal part of the aorta is 
replaced by a Dacron tube. In case of associated aortic root involvement, also the root is placed by 
a vascular graft with re-implantation of the coronary arteries (David procedure). If the aortic valve 
can’t be repaired, the aortic valve, root and ascending aorta are replaced with a composite graft with 
re-implantation of the coronary arteries (Bentall procedure). Aneurysms of the descending aorta are 
treated with endovascular therapy if feasible, given the morbidity associated with open procedures. 
[15] 
In the general population, patients with an uncomplicated type B dissection are mostly treated 
medically. Surgical or endovascular intervention is reserved for patients with a complicated course. 
It is unclear whether this strategy also applies for TS patients [144]. 
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Risk factors for aortic dissection 
Risk factors for aortic dissection are the presence of a CHD (coarctation, BAV) or arterial 
hypertension. The majority of TS with aortic dissection have one or more risk factors, but dissection 
is also described in TS patients without a cardiac malformation, aortic aneurysm or hypertension 
[19, 20, 61]. 
The impact of pregnancy on the risk for aortic dissection remains the subject of discussion. 
Retrospective study of published case reports suggests that pregnancy in TS increases the risk for 
aortic dissection and report a maternal demise of 2% [79]. On the other hand, in a large Swedish 
study in 124 childbearing TS patients, there was no maternal death [67]. The incidence of aortic 
aneurysm was similar in the TS group with or without pregnancy (2.4 versus 2.2%). Two of the 3 TS 
patients who developed an aneurysm during pregnancy or in the postpartum period had a 
concomitant cardiac problem. 
As pregnancy increases the risk for aortic dissection in TS patients with pre-existing CHD or aortic 
dilation, rigorous preconceptional cardiovascular screening and counselling is mandatory. 
Pregnancy is contraindicated in TS patients with previous cardiac surgery, aortic coarctation, severe 
dilation of the aorta defined as ASI ≥25 mm/m² or uncontrolled hypertension. [17] 
Comparison with the general population 
In the general population dissection occurs with an incidence of 2.9/100 000 patient years [102] at a 
mean age of 63 years [66]. Like in TS, Stanford type A dissections are the most frequent (70-75%) 
[88, 102]. Men are more at risk for aortic dissection than women [66]. Mortality after acute type A 
dissection in the general population varies between 10 and 35% for patients who are surgically 
treated [144]. 
 
I.3.2.4 Vasculopathy beyond the aorta 
Apart from the aorta, abnormally large diameters are also found in the carotid, subclavian and 
brachial arteries of TS women [109, 126]. In a group of young TS patients, the stiffness of the 
carotid artery was increased compared to controls, suggesting a vasculopathy that reaches beyond 
the aorta [90]. 
Although not studied in a large population, the vasculopathy in TS seems to extend into the brain. 
The odds to die from a cerebrovascular accident are increased 4 fold in TS [141]. Large datasets or 
reviews on cerebrovascular pathology in TS are lacking but several case reports describe severe 
cerebrovascular accidents in young TS patients: atherosclerosis, congenital carotid hypoplasia, 
dissection of the internal carotid artery with cerebri media infarction and Moyamoya disease [47, 50, 
76, 76, 78, 83, 111, 123, 152]. 
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I.3.3 Arterial hypertension 
Definition of normal and increased blood pressure 
Blood pressure in children varies with age. Blood pressure percentiles for sex, age and height are 
available for in office [115] and 24 hour ambulatory [165] measurements. Blood pressure values 
above the 95
th






According the the European Society of Cardiology  blood pressure in adults is considered too high if 
in office blood pressure exceeds 140/90 mmHg or if the mean 24 hour blood pressure exceeds 
130/80 mmHg [97]. However, in the TS literature, different definitions of hypertension are used, 
complicating comparison of data [37]. 
Prevalence in TS 
Hypertension is a common problem in TS. It is reported in 13 to 58% of adult [4, 42, 62, 71, 86, 126, 
134, 160] and in 25% of the paediatric [1, 49] TS patients. The large variance in the reported 
prevalances can probably be explained by differences in race and lifestyle and by the different 
definitions of hypertension used in the various study protocols. Insufficient nocturnal dipping is a 
common finding on 24 hour ambulatory blood pressure monitoring both in adults [51, 63] and 
children [1, 49, 114]. Although some groups found that TS patients preferentially suffer from isolated 
diastolic hypertension, this is not confirmed by others [37]. 
 
Figure 6:  algorithm for the follow-up and treatment of hypertension in TS patients. Adapted from K 
De Groote et al. [37].  * Cardiovascular defects: bicuspid aortic valve, aortic coarctation 
or dilation of the ascending aorta >20 mm/m². 
TS patients with additional cardiovascular risk factors are treated according the 
international guidelines on arterial hypertension [97] 
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Clinical significance 
Hypertension is a well known risk factor for cerebrovascular accidents and aortic dissection and 
contributes to the increased morbidity and mortality of TS. The relative risk for hypertension related 
morbidity is 2.9 (95% CI 1.9–6) [60] and death related to hypertensive disease is six times higher 
than in the general population (SMR 6.0, 95% CI 1.2–17.5) [141]. 
Treatment (figure 6) 
Hypertension contributes highly to the negative prognosis of TS and therefore needs rigorous 
follow-up and treatment. Cut off values for the initiation of medical treatment and blood pressure 
targets in TS remain a subject of debate as interventional studies in this population are laking. In 
view of the increased risk for aortic dilation and the established detrimental effect of hypertension in 
the evolution to aortic dissection or rupture, lower blood pressure thresholds seem appropriate in TS 
patients with CHD [27, 155]. Treatment of hypertension includes adaptation of a healthier life style, 
anti-hypertensive medication and treatment of concomitant diseases as diabetes and thyroid 
dysfunction. 
There are no data comparing different antihypertensive therapies in TS patients. Current treatment 
strategies are guided by clinical experience and common sense (table 4). 
Table 4: antihypertensive treatment based on associated pathology 
Indication Initial treatment 
Isolated hypertension Beta-blocker 
If contra-indicated or not tolerated: ACE-inhibitor or 
angiotensin receptor blocker or calcium channel blocker 
Associated dilation of the aorta Beta-blocker 
If contra-indicated or not tolerated: angiotensin receptor 
blocker 
Associated systolic ventricular 
dysfunction 
ACE-inhibitor 
Angiotensin receptor blocker 
Beta-blocker 
Associate a diuretic if necessary 
Associate a mineralocorticoid receptor blocker if necessary 
Associated left ventricular 
hypertrophy 
ACE-inhibitor 
Angiotensin receptor blocker 
Beta-blocker 
Calcium channel blocker  
Associate a diuretic if necessary 
Associate a mineralocorticoid receptor blocker if necessary  
Metabolic syndrome ACE-inhibitor 
Angiotensin receptor blocker 
Calcium channel blocker 
Pregnancy Beta-blocker 
Methyldopa 
Associate long-acting calcium channel blocker if necessary 
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Most groups prefer the use of beta-blockers, given their favourable effect on aortic dilation in Marfan 
syndrome [11, 27, 155, 169] but it must be noted that a similar effect in TS is not proven. However, 
they have a positive effect on the sinus tachycardia that is frequently encountered in TS [58, 169]. 
Beta-blockers can increase the risk for glucose intolerance and are relatively contra-indicated in 
patients with asthma. As some studies show an increased RAA activation in Turner syndrome, 
ACE-inhibitors (ACE-I) or angiotensin receptor blockers (ARB) are a reasonable alternative [160]. 
Losartan was found to have an additive effect to beta-blocker therapy in the treatment of aortic 
dilation in Marfan syndrome patients [64, 105] but again this is not studied in TS patients. Both 
ACE-I and ARB have teratogenic properties and cannot be used during pregnancy or the IVF 
process. 
A systematic review on the prevalence and aetiology of arterial hypertension in TS is added as an 
appendix to this PhD thesis (Chapter VI, pa 135). It describes the relation between blood pressure, 
aortic dilation and increased cardiovascular risk. Current treatment strategies are reviewed and an 
integrated practical approach for the diagnosis and treatment of hypertension in Turner syndrome 
applicable in daily practice is proposed. 
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I.3.4 ECG abnormalities and sympathic dysregulation 
Definition 
The ECG of TS girls differs from that of normal controls. They show a higher resting heart rate 
(91±15 bpm vs. 76±11 bpm), shorter PR (127±16 ms vs. 144±26 ms) and a longer QTc interval 
(431±22 ms vs. 407±21 ms) [12, 14, 33]. A QTc interval > 440 ms is found in 20 to 36% of TS girls 
[12, 34]. During exercise test and increasing heart rates, the QTc interval normalises [34]. 
Adult TS patients have higher resting heart rates [58, 169] with increased norepinephrine levels and 
similar epinephrine levels compared to normal controls [169]. Although the physical physiological 
response to exercise is normal in TS patients (normal increase in blood pressure and heart rate), 
the exercise-induced surge of epinephrine levels is lower in the TS patients [169]. These findings 
suggest a dysregulation of the sympathic nervous system [58, 169]. 
Prevalence 
Only one study describes the prevalence of ECG abnormalities in young TS patients: a QTc interval 
that exceeds 440 ms was found in 35% [12]. 
Clinical significance 
Although the QTc interval of TS patients is prolonged compared to normal controls, clinically 
significant “long QTc syndrome” is rare. There is no apparent relation between the ECG alterations 
and an increased risk for life threatening rhythm disorders in TS. However, literature describes one 
case of sudden death in a 17 year old with TS and a mildly prolonged QTc. 
In a group of 40 TS women with a QTc interval >432 ms, 8 genetic mutations were found: 6 in 
KCNH2 and 2 in SCN5A. There is however no genetic explanation for the apparent co-segregation 
of long QTc mutations with the complete or partial loss of an X chromosome in TS. 
Treatment 
Clear guidelines are lacking, but it seems wise to avoid all QTc prolonging drugs in TS patients with 
a prolonged QTc interval on resting ECG. Treatment with antiarrhythmic drugs can be considered in 
selected cases [33]. Although there are no comparative studies on the use of drugs for long QTc in 
TS, the use of a betablocker seems appropriate. Data on the usefulness of routine 24 hour holter 
monitoring in TS patients are lacking. 
Comparison with the general population 
In the general population, the reported prevalence of long QTc syndrome is 1/2000 [142]. At least 
14 mutations are known to cause the syndrome [113]. Apart from avoidance of QTc prolonging 
medication, treatment consists of anti arrhythmic drugs and in selected cases the implantation on an 
ICD (Implantable Cardioverter Defibrillator). 
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I.3.5 Cardiovascular disease in Turner, the role of the second heart field and the 
neural crest 
Modern insights into the embryogenesis of the human heart help to explain the particular 
association of the cardiovascular abnormalities in TS [52]. Heart development is a complex process 
during which the heart transforms from a single tube towards a fully septated heart with four 
chambers and a separated outflow tract. Initially, the mesoderm of the first heart field gives rise to 
the primary heart tube that consists of a small atrial component connected to the sinus venosus, an 
atrioventricular canal, a ventricular inflow tract and a small outflow tract connecting to the aortic sac. 
The dorsally positioned mesoderm, the second heart field, reaches to the heart tube at both the 
arterial and the venous poles. At the venous pole, the posterior second heart field gives rise to the 
sinus venosus, the dorsal wall of both atria and the primary atrial septum. At the arterial pole, the 
anterior second heart field supplies the myocardium of the right ventricle and the right side of the 
septum. The anterior second heart field also contributes to the semilunar valves and the walls of the 
great arteries. At the distal end of the two main endocardial outflow tract ridges in the still 
unseptated arterial orifice level, two small intercalated cushions appear. During normal 
development, separation of the arterial orifice level results in three semilunar valve leaflets in the 
aortic and pulmonary orifices. Abnormal separation can lead to the occurrence of a bicuspid aortic 
valve. There are indications that the anterior second heart field is not only involved in the formation 
of the aortic valve but also of the wall of the ascending aorta. 
For subsequent remodelling, septation, valve formation and coronary vascular development two 
other cell populations, the neural crest cells and the epicardium, are added to the heart. Aortic arch 
malformations are often linked to a deficient interaction of neural crest cells and the anterior second 
heart field. Neural crest cells also contribute to the development to the autonomic nervous system 
and cells that are important for the differentiation of the cardiac conduction system (CCS). 
Based on this new insights, it appears that the complex cardiovascular pathology of Turner 
syndrome is related to an abnormal development of the anterior second heart field (explaining the 
presence of a bicuspid aortic valves and abnormal stiffness of the ascending aorta), an abnormal 
development of the neural crest cells (explaining the sympathic dysbalance and the conduction 
abnormalities) and a deficient interaction between the neural crest cells and the anterior second 
heart field (explaining the abnormal aortic arch morphology). Until now, it remain unknown which 
genes are involved in this process. 
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I.4 Endocrine pathology with an impact on cardiovascular health of 
Turner patients 
I.4.1 Metabolic risk factors for cardiovascular health 
TS patients exhibit a variety of endocrine and metabolic disorders that add to their increased 
cardiovascular burden [100]. Hyperglycemia, obesity and hyperlipidemia are highly prevalent in TS. 
They are well known risk factors for atherosclerosis, an established precursor of cardiovascular 
disease. Atherosclerosis presents in TS from a young age on [1, 4, 126] and adds significantly to 
the morbidity [60] and the mortality [141] of the syndrome. 
 
I.4.1.1 Impaired glucose metabolism 
Girls and women with TS are at an increased risk for impaired glucose metabolism and type 2 
diabetes. Glucose intolerance presents in 15 to 50% [56] and diabetes type 2 in 10% of TS patients 
[57]. Both are found from childhood on [23, 120, 120]. The risk for glucose intolerance is the highest 
in patients with monosomy X0 and isochromosome Xq, suggesting haploinsufficiency of genes on 
Xp as a major cause [23]. The exact pathophysiology of the impaired glucose metabolism remains 
subject of debate. Both reduced insulin secretion and impaired insulin sensitivity are described 
[100]. 
 
I.4.1.2 Obesity and unfavourable body composition 
Overweight and obesity form a major health problem in TS [43]. Adult and paediatric patients show 
an increased weigh and BMI, an increased waist circumference, a higher percentage of whole-body 
fat mass, a decreased lean body mass and increased visceral fat [59, 120, 128]. This unfavourable 
body composition contributes to the development of insulin resistance, diabetes type 2 and the 
metabolic syndrome. 
 
I.4.1.3 Lipid abnormalities 
Data on the lipid level of TS patients are inconsistent, both in the paediatric and the adult population 
[1, 43, 86, 139]. Although some describe a less favourable lipid profile with increased total 
cholesterol, increased triglycerides, increased low density cholesterol and decreased high density 
cholesterol, this is not confirmed by others. 
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I.4.1.4 The metabolic syndrome 
Patients who exhibit at least 5 cardiovascular risk factors have the so called “metabolic syndrome” 
and carry the highest cardiovascular risk: 
 Obesity, defined as a BMI above the 95
th
 percentile for age and gender 
 Systolic or diastolic blood pressure above the 95
th
 percentile for age, height and gender 
 Triglyceride level above the 95
th
 percentile for age and gender 
 High density cholesterol levels below the 5t
th
 percentile for age and gender 
 Glucose intolerance or diabetes type 2 
As described above, all these risk factors are highly prevalent in TS and present from childhood, 
making TS patients at an increased risk for the metabolic syndrome. 
Because of the increased risk of for the before mentioned endocrine disorders, follow-up of TS 
patients include regular screening of weight, lipid profile, glucose metabolism and blood pressure. If 
risk factors are present, they should be rigorously treated. Preventive measures however remain of 
uppermost importance and include promotion of a healthy life style with sufficient physical activity 
and a healthy diet. 
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I.4.2 Premature ovarian failure and estrogen replacement therapy 
Premature ovarian failure in Turner syndrome 
TS is characterised by premature ovarian failure and sex hormone deficiency. The lack of estrogens 
and androgens highly contributes to the burden of TS as it causes abnormal bone maturation, 
osteoporosis, absent secondary female sex characteristics and infertility, abnormal cognitive 
development and cardiovascular disease. 
Estrogen replacement therapy in Turner syndrome 
Estrogen deficiency is responsible for the absent or arrested puberty in TS. Spontaneous initial 
pubertal development occurs in only 10 to 30% of girls with TS. The majority requires hormonal 
induction with increasing doses of estrogens and progesterone [11]. In adult life, sex hormone 
replacement therapy (HRT) is promoted to improve bone mineral density and overall body 
composition. Natural 17  β-oestradiol is the preferred type of estrogen. It can be administered both 
orally or transdermally [153]. 
The impact of hormone replacement therapy on the cardiovascular status 
HRT could theoretically have a lipid lowering and anti-oxidant effect, enhance endothelial function, 
antagonise the renin-angiotensin-aldosterone system and improve insulin sensitivity. The 
cardioprotective effect of prophylactic HRT in postmenopausal women is however disappointing as 
it does not reduce the cardiovascular risk but increases the risk for breast cancer, venous 
thromboembolism and stroke. 
The positive effect of HRT on the cardiovascular risk in TS remains subject of debate [153]. In 
young women with various causes of premature ovarian failure, physiological doses of HRT resulted 
in lower systolic and diastolic blood pressure, better renal function and less activation of the renin-
angiotensin system [87]. Studies on short term HRT in TS also show a positive effect on 24 hours 
diastolic blood pressure [63, 108] but long term prospective studies are lacking. Few studies exist 
on the effects of estrogen replacement on the arterial wall. Mortensen et al. did not find any effect of 
HRT on arterial stiffness nor on lipid profile in TS [108]. Using increasing doses of 17β-oestradiol, 
Ostberg et al. found an increased HLDL and decreased LDL cholesterol with a significant reduction 
in carotid intima-media thickness but without significantly improving blood pressure or arterial 
stiffness [127]. 
  
The call to the adventure 
37 
I.4.3 Small stature and exogenous growth hormone treatment 
Small stature in Turner syndrome 
Haploinsufficiency of the SHOX genes is the primary cause of the reduced final height and 
abnormal body proportion of TS patients [84]. Altered IGF-I activity, caused by reduced 
bioavailability and/or reduced sensitivity, probably contribute to the phenomenon [163]. 
Growth hormone treatment in Turner syndrome 
Treatment with supraphysiologic doses of exogenous recombinant human growth hormone (GH) is 
widely used to increase adult height of TS patients. If the diagnosis is made early, treatment is 
usually started at a young age [11]. 
The impact of growth hormone treatment on the cardiovascular system 
Exogenous growth hormone treatment in adults causes sodium and water retention with increased 
levels of plasma renin activity and aldosterone levels leading to hypertension [7]. These changes 
are not observed in children [7]. In healthy adult volunteers, administration of supraphysiologic 
doses of GH, similar to those used in the treatment of TS children, results in a concentric 
hypertrophy with an increased left ventricular mass index and an increased cardiac output [25]. 
Prospective longitudinal data on the impact of GH treatment in TS are lacking. Cross-sectional data 
showed that long-term administration of GH does not induce left ventricular hypertrophy or alter 
systolic and diastolic function [99, 138, 157]. GH treatment has no effect on abnormal aortic growth 
as an MRI study showed similar aortic diameters in women with and without GH treatment in 
childhood [13]. The effect of GH on blood pressure remains less clear. In an Italian cross-sectional 
study, TS girls treated with high doses of growth hormone (1U/kg/week) had an increased systolic 
and a decreased diastolic blood pressure compared to age and BSA-matched healthy girls without 
GH treatment [138]. In a Dutch study comparing different regimens of GH registration, only TS girls 
receiving high doses (2.7 mg/m² BSA/day) of GH for several years, showed a decreased diastolic 
blood pressure while systolic blood pressure was not affected [157]. This positive effect of growth 
hormone on diastolic blood pressure was however not sustained after discontinuation [5]. In TS 
patients receiving standard doses of GH (1.3 mg/m²BSA/day and 2.0 mg/m² BSA/day) no changes 
in blood pressure were observed [157]. 
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I.5 Non-invasive techniques for the evaluation of the aorta 
Evaluation of the aorta in TS includes evaluation of the aortic valve, the aortic root, the ascending 
aorta, the transverse arch, the descending and the abdominal aorta (figure 6). The aorta can be 




Figure 7: schematic representation of the aorta [44] 
 
Ultrasound is a readily accessible, quick (real time assessment) and cheap technique with no 
adverse events. It is very well tolerated by patients of any age. The result from the ultrasound exam 
however depends highly on the experience of the observer and the body composition of the patient. 
In TS, ultrasound imaging can be hampered by an increased anteroposterior thoracic diameter 
(“barrel-shaped thorax”) [72] and obesity. In a large group of 253 TS patients of variable age, 
echocardiography failed to visualise the aortic valve morphology in 6%, while visualisation was of 
moderate quality in another 4% [140]. Visualisation of the distal aorta is difficult and less reliable. 
Besides the evaluation of the aorta and great vessels, ultrasound allows identification of intracardiac 
lesions and evaluation of systolic and diastolic ventricular function. 
Ultrasound can also be used to measure the elastic properties of the aortic wall. In clinical practice, 
pulse wave velocity (PWV) is routinely used as it the most important independent predictor of 
cardiovascular events in adults. The measurement is based on the time it takes for the pulse to 
travel from one place to another. The distance travelled by the pulse is measured with a measuring 
tape on the body of the patient. Other parameters of arterial stiffness that can be derived by 
ultrasound are distensibility and stiffness index of the ascending aorta. Both are based on the 
difference in arterial diameter during systole and diastole. The ascending aorta is visualized from 
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the parasternal axis in a horizontally plane and measurement of the aortic diameters is performed at 
the site of the right pulmonary branche thus enabling standardized imaging. In children, the 
ascending aorta can be visualized nicely in the majority of cases. Normal values for distensibility 
and arterial stiffness index, based on a large population of German children, are available [68]. In 
adults, horizontal visualisation of the aorta is more difficult and in TS images are additionally 
hampered by obesity and the barrel shape of the thorax. Normal values for echo derived 
distensibility and stiffness index in adults are lacking . 
MRI is superior to ultrasound when it comes to visualisation of the entire aorta, but appreciation of 
the aortic valve morphology does fail in some cases (1-2%) [140]. MRI allows determining 
ventricular volume and ventricular mass in a reproducible way. In patients with poor transthoracic 
visualization, MRI is favourable for the diagnosis of PAPVC, LSVC and coarctation. 
MRI is a useful tool for the evaluation of the elastic properties of the aortic wall. The use of MRI for 
measuring PWV has 2 major advances as compared to ultrasound. The distance travelled by the 
pulse can be exactly measured inside the vessel, taking into account abnormal aortic arch 
morphology. Secondly, the PWV can be measured between any 2 locations on the aorta, enabling 
determination of separate PWV values for different segments of the aorta. Distensibility and 
stiffness index can also be derived from MRI images. MRI allows good quality imaging in all patients 
but requires a long scanning time. Normal values are available both for children [161] and adults 
[80]. 
In contrast to ultrasound, MRI is an expensive technique and access is limited to specialised 
centres. In some specific cases, imaging MRI is not possible: in patients with pacemakers or 
implantable cardioverter defibrillators (ICD’s), vascular clips, cochlear implants, neural stimulators, 
epileptic seizures, large tattoos, significant claustrophobia or morbid obesity. A complete MRI 
investigation is time consuming and requires a good cooperation of the patient. In young children, 
the technique is not applicable unless the patient is sedated. 
CT imaging allows morphologic evaluation of the entire aorta and the aortic valve. It is also a 
valuable diagnostic tool for the diagnosis of PAPVC, LVCS and aortic coarctation. Moreover, the 
technique is superior to MRI when it comes to visualization of the coronary arteries. 
In comparison with MRI, the scanning time of the CT is shorter, which makes an imaging study 
without sedation at an early age easier. However, CT imaging requires radiation and intravenous 
contrast administration. Furthermore, functional evaluation of left ventricle and aortic wall is not 
possible without an unacceptably high radiation dose. Although CT is less expensive than MR, the 
need for radiation is the main reason why CT is less frequently used in research protocols. 
As is the case for most CHD, imaging techniques are complementary when it comes to a complete 
cardiovascular evaluation. The technical details on the specific measurements used in the research 
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II.1 Contribution of cardiovascular pathology to the mortality in Turner 
syndrome 
Morbidity and mortality are increased in TS compared to the general population. 
A large multicenter study in the UK described the most frequent causes of death in TS [141]. The 
authors calculated that the mortality in TS is 3-fold higher than in women of the same age category 
in the general population. Although mortality is raised for almost all major causes of death, 
cardiovascular pathology plays the most important role. The standardised mortality rates (SMR) for 
all major cardiovascular disease are listed in table 5. 
 
Table 5: SMR for cardiovascular pathology in Turner syndrome 
Pathology SMR 95% CI 
Aortic aneurysm 23.6 13.8 – 37.8 
Congenital heart disease 20.7 11.8 – 33.7 
Aortic valve disease 17.9 4.9 – 46 
Hypertension 6.0 1.2 – 17.5 
Cerebrovascular disease 3.9 2.6 – 5.6 
Ischemic heart disease 2.8 1.9 – 3.8 
SMR: standardised mortality rate (ratio of the number of observed to the number of expected 
deaths in a similar age group) for the whole TS cohort [141] 
 
The risk for dying from an aortic dissection is 23.6 (CI 13.8-37.8) times higher in TS patients than in 
the general female population under the age of 85 years [141]. This risk is specifically increased in 
the younger age groups (278 times higher for the age group 15 to 44 years vs. 7.4 times higher for 
the age groups 45 to 84 years) [141]. 
Current guidelines on follow-up and treatment of TS therefore include regular cardiovascular 
examination and rigorous treatment of risk factors for aortic dissection [3, 11, 133]. Risk stratification 
for aortic dissection includes assessment of aortic valve morphology, coarctation, aortic diameters 
and blood pressure. However, retrospective analysis showed that 5 to 11 % of TS with dissection 
had neither a CHD nor hypertension [19, 20, 61]. 
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II.2 Knowledge gaps in the pathophysiology of aortic dilation in Turner 
syndrome 
Data on the histological structure of the aortic wall of TS patients, either with or without dilation, are 
scarce. Gravholt et al. reported data on the biopsy of 6 TS patients with aortic dissection that 
showed cystic media necrosis in 3, fibrous degeneration in 2 and increased amounts of acid 
mucopolysaccharides in 1 [61]. They also described an altered ratio between type I and type III 
collagen [61]. In the tissue of ascending aortic aneurysms associated with other pathologies like 
Marfan syndrome or in association with bicuspid aortic valves, elastic fibre destruction, mucoid 
accumulation, and smooth muscle cell apoptosis have been found. In the specimens of these 
patients dysregulation of TGF-ß retention and Smad2 signalling play a major role [54]. 
TGF-ß seems also involved in TS. In TS patients, serum TGF-ß1 levels are about 3-fold higher than 
in controls while TGF-ß2 levels are about 3.5-fold lower. There is no difference in TGF-ß levels 
between patients with or without aortic pathology, suggesting that all TS patients might have 
abnormal aortic wall properties [168]. 
Recently, research in TS patients suggested that aortic dilation is associated with an intrinsic 
abnormal elasticity of the aortic wall. In one publication, aortic dilation was inversely correlated with 
aortic distensibility in a group of TS of varying age but an abnormal distensibility was also found in 2 
TS girls with normal aortic dimensions [143]. In another group of young TS patients, PWV and 
augmentation index were impaired compared to lean and obese non-TS patients. The authors did 
not find any correlation between the presence of vasculopathy and CHD, growth hormone treatment 
or the administration of estrogen [90]. In a group of young TS adults previously treated with growth 
hormone, aortic distensibility was decreased [158]. In contrast to the previous reports, a German 
study found similar aortic compliance in young TS patients compared to normal male and female 
controls [82]. 
Longitudinal data on the vascular wall changes as well as histological studies of the aortic wall in TS 
could help to understand the aetiology of aortic dilation. However, research in this field is hampered 
by the lack of animal TS models making clinical research of most importance. 
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II.3 Quest for the missing link: research questions for the PhD research 
Aortic dilation is the most important risk factor for aortic dissection in TS but the exact aetiology of 
this process is not completely understood. In this thesis, different factors that could contribute to 
aortic dilation in TS were explored in a clinical research setting. 
The following research questions were formulated: 
1. Is there a relation between aortic dilation and CHD and X chromosome 
haploinsufficiency? 
Cardiovascular pathology in males and females with 45,X/46,XY mosaicism. 
Katya De Groote, Martine Cools, Jean De Schepper, Margarita Craen, Inge François, Daniel 
Devos, Karlien Carbonez, Benedicte Eyskens, Daniel De Wolf.  
PlosOne 2013; 8(2): e54977. 
 
2. Is there a relation between aortic dilation, aortic arch morphology and hypertension in 
adult TS patients? 
Abnormal aortic arch morphology in Turner syndrome patients is a risk factor for hypertension. 
Katya De Groote, Daniel Devos, Koen Van Herck, Laurent Demulier, Wesley Buysse, Jean 
De Schepper, Daniel De Wolf. 
Heart and Vessels 2015; 30: 618-625. 
 
3. Is there a relation between aortic dimensions, aortic valve morphology and aortic wall 
stiffness in TS children and adults? 
3.1. In prepubertal TS girls 
Increased aortic stiffness in prepubertal girls with Turner syndrome. 
Katya De Groote, Daniel Devos, Daniel De Wolf, Koen Van Herck, Saskia Van der Straaten, 
Ernst Rietzschel, Ann Raes, Kristof Vandekerckhove, Joseph Panzer, Hans De Wilde, Jean 
De Schepper. 
Journal of Cardiology, in press. 
 
3.2. In TS children and adults 
Proximal aortic stiffening in Turner patients is more pronounced in the presence of a bicuspid 
valve. A segmental functional MRI study. 
Daniel Devos, Katya De Groote, Danilo Babin, Laurent Demulier, Yves Taeymans, Jos 
Westenberg, Luc Van Bortel, Patrick Segers, Eric Achten, Jean De Schepper, Ernst 
Rietzschel. 
Currently unpublished, preliminary results. 
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II.4 Description of the populations studied 
The table below describes for each study the TS population studied, the control group if included 
and the evaluation technique that was used. 
 
Table 6: Description of the populations studied in the PhD thesis 







0 - 38 None Echo and 
MRI 
2 Ghent University 
Hospital  
Adult TS with at 
least 1 routine MRI 
74 18 -59 None MRI 
3 Ghent University 
Hospital 





4 Ghent University 
Hospital 
TS with at least  
1 MRI 
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II.5 Description of the cardiovascular evaluation techniques used 
The non-invasive ultrasound and MRI techniques used for the evaluation of the aorta in the clinical 
research protocols are described. 
 
II.5.1 Evaluation of aortic morphology and aortic diameters 
II.5.1.1 Evaluation by ultrasound 
Echocardiography was performed with the use of a VIVID 7 ultrasound (GE Vingmed Ultrasound, 
Horten, Norway) equipped with a 3,5 MHz probe. Data were stored and used for off line analysis 
using EchoPAC version 110.1.0 software (GE Vingmed Ultrasound). 
Aortic valve morphology was studied by 2D echo on the parasternal short axis and included 
evaluation of the number of cusps, the presence of a raphe and the functional opening. Aortic valve 
insufficiency and stenosis were quantified on the parasternal short and long axis using colour and 
CW Doppler. 
Diameters of the aorta were measured from the parasternal long axis at the level of the aortic valve 
annulus, the aortic root and the ascending aorta (figure 8). Measurement of the transverse arch was 
obtained from the suprasternal notch. Normality of the data was determined by using the z-scores, 
as described earlier in the first chapter. 
 
 
Figure 8: measurements of the aortic dimensions at the site of the aortic annulus (left) aortic root 
(middle) and ascending aorta (right) 
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II.5.1.2 Evaluation by MRI 
Cardiac MRI was performed by an experienced radiologist on a 1.5T magnet (Siemens Avanto, 
Erlangen) and included the use of intravenous contrast medium (Gadobutrol at 1ml/10kg 
bodyweight). 
Morphologic and functional evaluation of the aortic valve was done on cine images of the left 
ventricular outflow and aortic valve plane; quantification of stenosis or regurgitation was performed 
by means of phase contrast images. 
Diameters of the aorta were measured on multiplanar reconstructed images perpendicular to the 
aortic lumen at the site of the aortic valve annulus, the aortic sinus, the sinotubular junction and the 
ascending aorta at the site of the right pulmonary artery, as well as at mid-arch between left carotid 
and subclavian ostium, and at proximal (at the level of the pulmonary artery bifurcation) and distal 
descending aorta (at the level of the diaphragm). 
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II.5.2 Evaluation of the elastic properties of the aorta 
The elastic properties of the aorta are classically described with the terms elasticity and stiffness. 
Distensibility or elasticity refers to the ability of a vessel to increase in volume without a significant 
increase in pressure. Stiffness or elastic resistance is the reciprocal and refers to the inability of a 
vessel to increase in volume. 
 
II.5.2.1 Evaluation by ultrasound 
Ultrasound evaluation of the vascular function was performed after minimal 20 minutes of rest. The 
data were acquired using a VIVID 7 ultrasound (GE Vingmed Ultrasound, Horten, Norway) 
equipped with a vascular transducer 12L set at 10 MHz . Data were stored and used for off line 
analysis using EchoPAC version 110.1.0 software (GE Vingmed Ultrasound). 
Pulse wave velocity of the aorta 
Pulsed Doppler signals were obtained consecutively at the right common carotid artery and the right 
femoral artery. The time interval (Δtime) between the arrival of the pulse at the carotid and femoral 
artery was calculated using the foot-to-foot velocity method [89] (figure 9). The distance between 
the carotid and the femoral artery (D carotid artery-femoral ) and between the carotid artery and the upper 
border of the sternum (D carotid artery-suprasternal notch ) was measured with a measuring tape. The distance 
(D) was calculated as the D carotid artery-femoral – D carotid artery-suprasternal notch. PWV was then defined as 
D/Δtime expressed in m/s. 
 
 
Figure 9:  PW Doppler signal at the femoral artery (upper part) and the common carotid artery 
(lower part). At both signals, the time interval is measured between the onset of the 
QRS complex and the onset of the systolic PW Doppler signal. Δtime is calculated as 
the difference between both time intervals. 
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Distensibility of the ascending aorta 
On the parasternal long axis, an M-mode image of the ascending aorta was recorded. Care was 
taken to place the aorta horizontally on the screen with the cursor perpendicular to the arterial wall 
at the level of the right pulmonary artery. On the M-mode recording, the diameter of the ascending 
aorta was measured from inner to inner surface during diastole and systole (figure 10). 
 
 
Figure 10:  M-mode recording of the ascending aorta on the parasternal long axis. The diameter 
of the ascending aorta is measured from inner to inner surface in diastole and systole. 
 
During the ultrasound exam, the blood pressure was taken 3 times and averaged for calculations. 




) were calculated 
based on the ascending aortic diameter in systole and diastole and on the pulse pressure. 
 
aortic stiffness index= 
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distensibility =  
   




      




    
  




                                                 
       (in 10-3kPa-1)] [68]. 
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II.5.2.2 Evaluation by MRI 
Pulse wave velocity of the aorta 
MRI derived PWV was measured for the thoracic aorta, the abdominal aorta and the entire aorta 
(figure 10). PWV was calculated as the ratio of distance Δx per time Δt, where Δx is the length of an 
aortic segment (thoracic, abdominal or entire aorta) measured on the MR image data along the 




Figure 11:  distance measurement along the aortic path (lines) and location of the aortic through-
plane flow velocity measurements (white stars). 
 
Distensibility of the ascending aorta 
On the MRI images, maximum and minimum transverse aortic luminal areas were manually located 
and drawn on the cine series. Distensibility was calculated as: 
Distensibility = 
               
                                                       
















III.1 The relation between X-chromosome haploinsufficiency, aortic 
dilation and other cardiovascular pathology 
 
Cardiovascular pathology in males and females with 45,X/46,XY mosaicism. 
Katya De Groote, Martine Cools, Jean De Schepper, Margarita Craen, Inge François, Daniel Devos, 
Karlien Carbonez, Benedicte Eyskens, Daniel De Wolf. 
PlosOne 2013; 8(2): e54977. 
 
In this study, the relation between X haploinsufficiency, aortic dilation and CHD was explored. The 
paper describes a Belgian multicentre study that investigated cardiovascular abnormalities in 
45,X/46,XY males compared to 45,X/46,XY females. 
 
Patients with 45,X/46,XY mosaicism were selected from the Belgian Registry for Growth and 
Puberty problems and via the multidisciplinary clinic for disorders of sexual development. Eighteen 
patients were included: 8 raised as females (F) and 10 as males (M). All 18 patients underwent a 
complete cardiac examination with blood pressure measurement, ECG and echocardiography by a 
single observer. An additional MRI was performed in 12. In a second phase, clinical features and 
external masculinisation score (EMS) were retrospectively collected from the medical files. 
 
Two patients had a history of a structural heart defect before inclusion: 1 F with coarctation and 1 M 
with a spontaneously closed VSD. During the study examinations, a bicuspid aortic valve was found 
in 8 (3F, 5M). Dilation of the ascending aorta was present in 4 M and was severe in 2 young boys 
(z-scores 4.48 and 6.19). QTc was prolonged in 3 F and 2 M. In male patients, cardiac pathology 
was more frequent in those who also had other TS related abnormalities. 
 
We concluded that males with 45,X/46,XY mosaicism have similar cardiovascular pathology as 
45,X/46,XY females. Dilation of the ascending aorta can be important, also in males. We advise 
cardiac screening and lifelong monitoring in all males with 45,X/46,XY mosaicism according to the 
existing guidelines for Turner syndrome. 
  





III.2 The relation between abnormal aortic arch morphology, 
hypertension and aortic dilation 
 
Abnormal aortic arch morphology in Turner syndrome patients is a risk factor for 
hypertension. 
Katya De Groote, Daniel Devos, Koen Van Herck, Wesley Buysse, Jean De Schepper, Daniel De 
Wolf 
Heart and Vessels 2015; 30: 618-625. 
 
In this study the association between abnormal aortic arch morphology and hypertension in adult TS 
patients was explored. We retrospectively revaluated the MRI images of 74 adult TS patients who 
underwent a cardiac MRI for routine follow-up. Aortic arch morphology was initially appreciated for 
normality based on the curve of the transverse arch and the distance the left common carotid - left 
subclavian artery. We additionally used a new more objective method to describe aortic arch 
abnormality in TS by determination of the relative position of the highest point of the transverse arch 
(AoHP). Based on the blood pressure in the medical files, TS patients were assigned to the 
hypertensive group (in office blood pressure ≥ 140/ 90 mmHg, 24h ambulatory blood pressure ≥ 
130/ 80 mmHg or use of antihypertensive treatment) or to the normotensive group. 
 
Thirty-one (42%) TS patients were hypertensive. When we evaluated the aortic arch morphology by 
the curve of the transverse arch, 20 TS patients had an abnormal aortic arch. When applying the 
quantitative measurement of the relative position of the highest point of the aorta, 19 arches were 
abnormal. Based on logistic regression analysis we showed that hypertension is significantly and 
independently associated with age, BMI and abnormal arch morphology, with a larger effect size for 
the new AoHP method than for the classical method. TS patients with hypertension and abnormal 
arch morphology more often had dilation of the ascending aorta. 
 
We concluded that there is a significant association between abnormal arch morphology and 
hypertension in TS patients, independent of age and BMI, and not related to other structural heart 
disease. We suggest that aortic arch morphology should be included in the risk stratification for 
hypertension in TS and propose a new quantitative method to express aortic arch morphology. 
  





III.3 The relation between aortic dilation and abnormal aortic stiffness in 
paediatric and adult patients with Turner syndrome 
 
In the 2 papers presented in this section, the relation between aortic dilation and abnormal aortic 
stiffness was explored in prepubertal TS girls and older TS patients. 
 
The first paper reports a study on aortic diameters, distensibility and stiffness index of the ascending 
aorta and pulse wave velocity (PWV) of the aortic arch, measured by ultrasound in 15 prepubertal 
TS girls and 31 age and height matched controls. 
 
The second part of this section reports preliminary results of a parallel study, in which MRI was 
used to measure pulse wave velocity (PWV) and distensibility of the thoracic and abdominal aorta in 
55 older TS patients (13-59 years) compared to 31 healthy controls. This study is currently 
unpublished, and enrolment is ongoing. 
  





III.3.1 The relation between aortic dilation and abnormal aortic stiffness, 
measured by ultrasound, in prepubertal patients with Turner syndrome 
 
This paper reports a study on aortic diameters, distensibility and stiffness index of the ascending 
aorta and pulse wave velocity (PWV) of the aortic arch, measured by ultrasound in 15 prepubertal 
TS girls and 31 age and height matched controls. 
The 6 TS girls with a bicuspid aortic had significantly larger ascending aortic diameters than the 
controls. Distensibility of the ascending aorta was lower and stiffness index was higher in the TS 
than in control group both for TS patients with a tricuspid aortic valve and a bicuspid aortic valve. 
The abnormality was however more pronounced for TS patients with a bicuspid aortic valve. PWV 
along the whole aortic arch was not different between groups. There was no correlation between the 
stiffness index and the z-scores of the ascending aorta. 
We concluded that the stiffness of the ascending aorta is increased in prepubertal TS girls in 
patients with a bicuspid and a tricuspid aortic valve while dilation of the ascending aorta is more 
severe in patients with a bicuspid aortic valve. This suggests that the aortic wall abnormality in TS is 
inherent to the chromosomal disorder, that probably all TS patients are at an increased risk for 
severe aortic complications but that the risk is the highest for those with a bicuspid aortic valve. 
  






III.3.2  The relation between aortic dilation and abnormal aortic stiffness, 
measured by MRI, in paediatric and adult patients with Turner syndrome 
 
The second part of this section reports preliminary results of a parallel study, in which MRI was used 
to measure pulse wave velocity (PWV) and distensibility of the thoracic and abdominal aorta in 55 
older TS patients (13-59 years) compared to 31 healthy controls. This study is currently 
unpublished, and enrolment in ongoing. 
TS patients had significantly higher PWV in the thoracic but not in the abdominal aorta. The 
diameter of the ascending aorta was significantly larger in TS compared to the controls. The 
increase in PWV and ascending aorta diameters were more pronounced in TS patients with 
bicuspid aortic valves compared to those with tricuspid valves. 
We concluded that adult Turner patients exhibit a predominant stiffening and dilation of the proximal 
aorta, especially if their aortic valve is bicuspid. These abnormalities are present from an early age, 
suggesting a limited effect of accelerated ageing. 
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IV.1 Aims and conclusions of the clinical studies 
Aortic dissection is a major problem in Turner syndrome and an important cause of early death [20, 
61, 141]. Since the first case reports on aortic dissection in TS in 1986 [92], several researchers 
focused on aortic pathology in this patient group. Although the knowledge increased impressively, 
not all risk factors are clearly defined and there still remain gaps in the risk stratification of aortic 
dissection in TS. 
 
This thesis aimed to add additional information on the aetiology of aortic dilation in TS. The 
following research questions were answered: 
1) Is there a relation between aortic dilation and CHD and X chromosome 
haploinsufficiency? 
In the first paper (III.1), a Belgian multicenter study compared cardiovascular abnormalities in 
45,X/46,XY female Turner patients with those in 45,X/46,XY males. Cardiovascular pathology, 
including BAV and dilation of the ascending aorta, was found in both groups, suggesting that 
aortic dilation and the other cardiovascular pathologies in TS are probably related to the X 
chromosome haploinsufficiency. 
 
2) Is there a relation between aortic dilation, aortic arch morphology and hypertension in 
adult TS patients? 
In the second paper (III.2), a retrospective MRI study explored the relation between abnormal 
aortic arch morphology and hypertension. There was a significant association in adult TS 
patients between abnormal arch morphology on MRI and hypertension that was not related to 
structural heart disease. TS patients with hypertension and abnormal arch morphology more 
often had dilation of the ascending aorta. This association between abnormal arch morphology, 
hypertension and aortic dilation suggests the presence of a common aetiology. Evaluation of 
the aortic arch morphology should be included in the follow-up of TS patients and could help 
improving the risk stratification for aortic dissection. 
 
3) Is there a relation between aortic dimensions, aortic valve morphology and aortic wall 
stiffness in TS children and adults? 
The third and fourth papers studied the relation between aortic valve morphology, aortic dilation 
and abnormal aortic stiffness. 
A prospective ultrasound study (III.3.1) compared aortic valve morphology, aortic dimensions 
and ascending aortic stiffness (stiffness index, distensibility and PWV) between prepubertal TS 
girls and healthy controls. The stiffness of the ascending aorta was increased in prepubertal TS 
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girls with a BAV and a TAV although the abnormality was more pronounced in those with a 
BAV. Severe dilation of the ascending aorta was only seen in TS girls with a BAV. There was no 
correlation between ascending aortic z-scores and stiffness index. 
A parallel MRI study (III.3.2) measured aortic dimensions, PWV and distensibility of the thoracic 
and abdominal aorta in older TS patients compared to healthy controls. TS patients had 
significantly higher PWV in the thoracic but not in the abdominal aorta. The diameter of the 
ascending aorta was significantly larger in TS patients. The increase in PWV and ascending 
aorta diameters were more pronounced in TS patients with BAV compared to those with TAV. 
Both studies show that TS patients have an abnormally stiff ascending aorta from a young age. 
This increased stiffness is also found in TS patients with a TAV and normal aortic dimensions. 
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IV.2 Research findings in relation to the current knowledge on risk 
factors for aortic dilation 
Dilation of the aorta is a major risk factor for aortic dissection. Several pathological processes have 
been put forward as possible causal or aggravating factors for progressive aortic dilation. In the 
following section, current knowledge on these factors will be discussed and supplemented with the 
results of the PhD research papers. 
 
Aging 
TS patients suffer from typical ageing diseases like type 2 diabetes, dyslipidemia, decreased bone 
density and hypertension. The increased growth velocity of the proximal aorta described in TS 
patients [110] has also been assigned to an accelerated ageing process. Indeed, the association of 
enlarged aortic diameters and age have been confirmed in several publications [42, 81, 110, 124, 
125] and dissection of the aorta occurs in TS at a much younger age than in the general population 
[20, 61]. 
Our study in young prepubertal girls confirmed the finding of others [21, 93] that large aortic 
diameters and abnormal aortic stiffness are already present in young children with TS, suggesting 
an intrinsic genetic pathology rather than a pure effect of accelerated ageing. 
 
Presence of a bicuspid aortic valve 
In the general population, BAV is associated with aortic dilation and an increased risk for aortic 
dissection [103, 166]. In BAV patients, the distensibility of the ascending aorta is impaired, both in 
adults [104] and in children [132]. This aortic wall abnormality is not only observed in BAV patients 
with aortic dilation but also in those with normal aortic dimensions [118, 119]. Histological studies in 
specimens of the human ascending aortic wall showed a dysregulation of TGF-ß retention and 
Smad2 signalling in syndromic and non-syndromic aneurysms [54]. Unfortunately, histological data 
in TS are very scarce. 
BAV are present in 14 to 40% of TS patients [39, 48, 55, 81, 94, 109, 136] and are associated with 
enlarged aortic dimensions [39, 93, 98, 109, 110, 124, 125, 137, 140]. However, larger aortic 
diameters, abnormally increased aortic growth [93, 107, 135] and aortic dissections [20] are also 
found in TS patients with normal tricuspid aortic valves. 
In our studies, aortic diameters of the TS patients were larger than those of controls while aortic 
dilation was more severe in TS patients with a BAV. Abnormal aortic wall stiffness on the other hand 
was present in TS patients with a BAV and a TAV, although it seemed more pronounced in the BAV 
group. This abnormal aortic wall property was present from early childhood on. This finding 
suggests that the abnormal stiffness of the ascending aorta in TS is not just secondary to the 
presence of a BAV but is inherent to the TS syndrome. 
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Future research comparing aortic dimension and aortic wall distensibility in non-syndromic patients 
with BAV and Turner patients could help to clarify the relative contribution of the intrinsic aortic wall 
property and the effect of BAV in TS. 
 
Presence of an aortic coarctation 
Coarctation of the aorta is found in 4 to 15% of TS patients [39, 48, 55, 72, 81, 94, 136]. It is 
associated with aortic dilation [110] and an increased risk for aortic dissection [19, 20, 61]. In the 
International Turner Syndrome Aortic Dissection Registry, 4 of the 20 patients with dissection had a 
history of aortic coarctation. Two of these patients had an associated aortic aneurysm but data on 
the aortic dimensions of the other 2 are missing. Until now it remains unclear whether an aortic 
coarctation can cause dissection if it is not associated with aortic dilation. 
In the general population, aortic coarctation is associated with an increased stiffness of the proximal 
aorta even after a successful surgical repair [85, 130, 162]. In our prospective study in prepubertal 
girls, the number of TS patients with coarctation (n=2) was too low to investigate a possible additive 
effect of coarctation on aortic stiffness. 
 
Abnormal aortic arch morphology 
Surgical repair of an aortic coarctation often results in an abnormal arch geometry that is described 
as “gothic” or “crenel. This gothic shaped aortic arch morphology is associated with hypertension 
and an increased stiffness of the proximal aorta [129-131]. A similar abnormal arch morphology with 
a late takeoff of the subclavian artery and a box shaped appearance of the arch (ETA) is frequently 
found in TS patients [72, 81, 109] with and without coarctation. A borderline significant association 
between ETA and aortic dilation is reported in literature [109]. 
In our retrospective MRI study we found an abnormal arch morphology in nearly one third of the TS 
patients. In line with previous data [72], there was a relation between abnormal aortic arch 
morphology and hypertension, irrespective of coarctation or other concomitant CHD. Moreover, we 
found that TS patients with an abnormal arch morphology more often had dilation of the ascending 
aorta. 
There are no data on the aortic arch morphology in TS children and it currently remains unclear 
whether ETA presents in childhood or whether it develops later in life. One could speculate that the 
aortic morphology is normal at birth and becomes more abnormal with age due to the increased 
stiffness of the ascending aorta that generates abnormal flow patterns in the aortic arch and creates 
aortic arch deformation. This phenomenon of abnormal flow could also explain the dilated head 
vessels that are frequently found in adult TS patients and that are associated with the presence of 
ETA [109]. 
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Unfortunately, we did not measure aortic distensibility in the retrospective MRI study. We are 
therefore unable to determine the relation between increased aortic stiffness and aortic arch 
morphology. Future research should focus on the longitudinal follow-up of aortic arch morphology 
using the quantitative measuring technique we described. The additional repetitive measurement of 
aortic distensibility could help to understand the role of aortic stiffness in the development aortic 
arch deformation. Computational flow models would be helpful to study flow alterations in stiff aortic 
arches and their possible association with arch deformation. 
 
Abnormal aortic stiffness 
Increased stiffness of the ascending aorta was previously described in TS patients of varying age 
[90, 143, 158]. It has been suggested a predictive risk factor for aortic dilation in TS since aortic 
dilation was associated with a decreased distensibility in one study [143]. However, in that same 
study, abnormal distensibility was also found in 2 TS children with normal aortic dimensions [143]. In 
another group of young TS patients aged 9 to 20 years, abnormal arterial stiffness of the aorta and 
the carotid artery was found irrespective of associated CHD [90]. 
In our prospective study, we found an abnormally decreased distensibility and an abnormally 
increased stiffness index in the ascending aorta of young prepubertal TS girls with a BAV and a 
TAV. We could not find an association between abnormal wall properties and aortic dilation in this 
young group. Severe ascending aortic dilation was only present in young TS patients with a BAV. 
Similar results for the elastic property were found in our prospective MRI study in adult TS patients. 
In these older patients aortic dilation was present in TS patients with a BAV and a TAV, although 
dilation was more pronounced in TS BAV patients. 
These data suggest that abnormal wall properties of the ascending aorta are inherent to the genetic 
problem and present from a young age on. This abnormal aortic stiffness probably plays a key role 
in the risk for aortic dissection but not necessarily through the process of severe aortic dilation. 
Large long term follow-up studies with focus on the evolution of aortic wall properties and the 
development of aortic dilation could help to understand the importance of abnormal stiffness in the 
evolution towards dilation and possibly dissection. 
 
Hypertension 
Abnormal arterial stiffness is the principal cause of increasing systolic pressure with advancing age 
and is associated with progressive arterial dilation in the non-TS population [29, 121]. In TS, 
hypertension is considered an important additional risk factor for aortic dilation and dissection. 
Several studies in TS patients confirmed a positive relation between arterial blood pressure and 
aortic dimensions [42, 71, 110] but data on arterial stiffness are lacking in these studies. It still 
remains to be clarified how abnormal arterial stiffness, hypertension and aortic dilation are 
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interrelated in TS. Theoretically, an intrinsic aortic wall abnormality could be the primary cause of 
both hypertension and dilation. 
Hypertension is reported in half of the adult and in one fourth of the paediatric TS patients [37]. In 
our study population, hypertension was present in 42% of the adults TS patients. The young 
prepubertal TS patients were all normotensive in office, but 24 hour ambulatory blood pressure 
measurement showed mild hypertension in 33% and abnormal nocturnal dipping in 41%. This 
discrepancy between in office blood pressure measurements and 24 hours blood pressure 
recordings has been reported previously [1]. 
In our prepubertal TS girls, we could not find any difference in blood pressure measured in office 
compared to controls, although TS girls showed marked aortic wall abnormalities. Unfortunately, the 
limited number of patients did not allow studying the relation between an abnormal 24 hour 
ambulatory blood pressure recording and abnormal aortic wall properties. Longitudinal follow-up of 
blood pressure and aortic stiffness is needed to see whether increased aortic stiffness leads to 
more pronounced hypertension in later life. 
In our retrospective MRI study we found that the combination of hypertension and abnormal arch 
morphology in TS patients is associated with dilation of the ascending aorta. Abnormal aortic 
stiffness -a theoretical common cause of abnormal arch morphology, hypertension and aortic 
dilation - could be the explanatory factor for this association. Unfortunately, we did not measure 
aortic distensibility in this retrospective study. Further analysis of the relation between aortic 
stiffness and aortic arch morphology, dilation and blood pressure could help to confirm or reject the 
hypothesis that an intrinsic aortic wall abnormality is the common cause of aortic arch deformation, 
hypertension and aortic dilation. 
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IV.3 Integrating the classical risk factors for aortic dilation in a general 
model 
As presented in the previous section, the aetiology of aortic dilation and dissection in TS is 
presumably multifactorial. In this paragraph a hypothetic model for the development of aortic dilation 
in TS is presented including all classical risk factors and their interactions (figure 12). 
 
The genetic defect of TS causes 4 cardiovascular problems that are related to aortic dilation and 
dissection (presented in a double line box): intrinsic vascular wall abnormality, hypertension, 
bicuspid aortic valve and coarctation. Each of these defects can contribute to the dissection 
process, either directly or via promotion of aortic dilation. In the figure, well accepted relations are 
presented in full lines, less established ones in dashed lines. 
 
 
Figure 12:  hypothetic model combining all different risk factors for aortic dissection. Well accepted 
relations are presented in full lines, less established ones in dashed lines. 
 
The increased stiffness of the ascending aorta in TS adds to the risk of aortic dissection by 
inducing arterial hypertension and aortic dilation but it probably also has a directly aggravating effect 
on the risk for dissection. In a normal situation with normal elastic aortic wall properties, the wave 
generated by the cardiac cycle travels along the aorta towards the periphery and is reflected back 
from that periphery. The pressure wave at any point along the aorta, is the resultant of the 
antegrade and reflected wave. In case of an increased aortic stiffness, the waves travel fast and the 
reflected wave merges with the systolic part of the incident wave causing a high pressure in systole 
[122]. Hypertension elevates the aortic wall stress thus promoting aortic dilation and increasing the 
risk for aortic dissection [30]. 
Increased stiffness of the ascending aorta is theoretically also one of the causes of the abnormal 
arch morphology that is frequently seen in TS and that is related to aortic dilation. Increased aortic 
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stiffness is more pronounced in TS with a bicuspid aortic valve and is seen patients with an aortic 
coarctation. 
 
Hypertension is associated with aortic dilation and is accepted as a major risk factor for aortic 
dissection both in the general and the TS population. Endocrine disorders, unfavourable body 
composition and sympathic over-activation increase the risk for developing high blood pressure and 
probably also add to the risk for aortic dissection. Hypertension is often seen in TS patients with 
coarctation or ETA. 
 
Aortic coarctation is associated with abnormal arch morphology, with dilation of the aorta, with 
increased stiffness of the ascending aorta and with arterial hypertension. It still remains unclear 
whether aortic coarctation is a risk factor for aortic dissection if it is not associated with aortic 
dilation. 
 
Bicuspid aortic valves are associated with dilation of the ascending aorta and progression towards 
aortic dissection. TS patients with a BAV have a more severe stiffening of the ascending aorta than 
those with a TAV. 
 
It is very likely that the individual risk of each TS patient depends on the presence and the severity 
off all factors described in the model. It remains unclear what the relative importance is of each 
individual abnormality but the presence of a bicuspid aortic valve and/or aortic dilation seems to be 
associated with the highest risk [19, 61]. It is likely that patients who combine several risk factors are 
more prone to progress towards dissection. Future research should focus on risk stratification 
including all dissection promoting pathologies, trying to classify patients into those with low, 
moderate and high risk on more than aortic diameters alone. Hypothetically, patients with an ASI 
<25 mm/m² might benefit for preventive surgery if they combine multiple risk factors like increased 
aortic stiffness, abnormal arch morphology, BAV and hypertension. On the contrary, it appears that 
TS patients with a TAV, normal aortic arch morphology, normal aortic elasticity, normal aortic 
diameters and normal arterial blood pressures have a very low risk for aortic dissection . 
Cardiovascular follow-up in these patients could probably be limited but until now prospective data 
are insufficient to reduce the number of visits to the cardiologist in clinical practice. 
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IV.4 New insights for the cardiovascular follow-up of TS patients 
Current guidelines on cardiovascular follow-up of TS patients focus on the diagnosis of the classical 
risk factors for aortic dissection: congenital heart defects, quantification of aortic dilation and 
hypertension. Repeated echocardiographic evaluation, at least every 3 to 10 year, in combination 
with regular cardiac MRI for an optimal visualisation of the aorta is advocated, also in patients 
without apparent cardiac problem [11, 27, 35, 41, 133]. Based on the data presented in this thesis, 
we concluded that abnormal aortic stiffness plays an additional role in the pathophysiology of aortic 
dilation and probably also in the progression towards dissection. It is therefore proposed to add 
measurements of aortic wall properties to the cardiovascular evaluation and follow-up of TS 
patients. 
Follow-up of the ultrasound derived PWV between the carotid and the femoral artery is of limited 
use in TS patients. In TS, abnormal aortic stiffness is limited to the proximal aorta and the 
measurement of the carotid-femoral PWV fails to detect this abnormality as is shown in papers 
III.3.1 and III.3.2. Moreover, the distance travelled by the pulse is measured with a tape measure 
from the carotid to the femoral measuring site but this presumes a normal aortic arch morphology 
without elongation or abnormal kinking. As TS patients often have an abnormal arch morphology, 
tape measure is not representative for the real aortic length. 
Follow-up of MRI derived PWV is possible in TS patients because the distance travelled by the 
pulse is measured exactly inside the vessel, taking into account abnormal elongation and kinking. 
Moreover, in contrast to ultrasound, MRI enables the selective measurement of the PWV of the 
proximal aorta. In adult TS patients, regular MRI is promoted to screen for progressive aortic 
dilation. Measurement of PWV could be included in the same exam. In paediatric TS patients, the 
use of MRI is complicated by the long duration of the image acquisition and the need for deep 
sedation in young children. It is therefore not the technique of first choice in this age group. 
The elastic property of the ascending aorta can be easily appreciated in TS children by the use of 
ultrasound derived distensibility and stiffness index. In adults, images are often hampered by 
obesity and the barrel shape of the thorax making this technique of limited use in this adult patient 
group. 
MRI derived distensibility and stiffness index allows good quality imaging in all patients but 
requires a long scanning time and sedation in young children. 
 
Based on the previous discussion, we propose to determine aortic stiffness repetitively in TS 
patients. 
In childhood ultrasound derived distensibility and stiffness index can be used as it easy to perform, 
cheap and well tolerated. In adults, it is more appropriate to use MRI derived PWV. Future 
longitudinal research however is necessary to compare the prognostic value of PWV and 
distensibility/stiffness index in the risk stratification for aortic dilation and dissection.  
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IV.5 Current protocol for the cardiovascular follow-up of Turner patients 
in Ghent University Hospital 
Benefits of cardiovascular follow-up 
Cost-benefit studies on the use of standardised follow-up of TS patients are lacking. Nevertheless, 
regular checkup including an elaborated cardiovascular examination is promoted in all international 
guidelines as there is no doubt about the increased cardiovascular risk in TS patients. Moreover, 
screening can theoretically lead to a decreased morbidity and mortality as treatment is available for 
several well established risk factors like hypertension, overweight, dyslipidemia and severe aortic 
aneurysm. 
 
Follow-up in the Ghent University Hospital, the historical perspective 
Before 2009, the cardiovascular follow-up and treatment of TS patients in the Ghent University 
Hospital was not standardised. At the moment of diagnosis, paediatric and adult patients were 
referred to the cardiologist for blood pressure measurement, ECG and echocardiography. If the 
initial screening showed a cardiovascular problem, further follow-up was scheduled based on the 
judgement of the treating physician. If the initial exam was normal, follow-up was not routinely 
organised. 
Since 2009, the follow-up and treatment of TS patients in the Ghent University Hospital is organised 
in a multidisciplinary Turner Clinic where staff members join regularly to discuss patients, protocols 
and research projects. Clinical care is centred in the paediatric or adult endocrinology department 
were all TS patients are examined at least yearly. Based on an internal protocol, patients are 
referred on a regular basis to the different caregivers involved. 
At the start of the Turner Clinic, the care for paediatric and adult TS patients was revisited and the 
first protocol on cardiovascular follow-up and treatment was established in 2009 [36]. In an 
international collaboration with the Dutch Turner Clinics, this subsequently evolved to the creation of 
the “Nederlands-Belgische richtlijnen voor de opvolging en behandeling van patiënten met het 
syndroom van Turner” that includes an elaborated chapter on the cardiovascular health of TS 
patients. With the advancing insights in the complex phenomenon of cardiovascular health in TS, 
partially based on the results of this PhD research, the protocol for cardiovascular follow-up and 
treatment has been refined. The most recent follow-up protocol is presented below (figure 13). The 
adaptations based on the new insights from this PhD research are marked in italic. The current 
insights in the treatment of cardiovascular disease in TS are described earlier in the introduction of 
this PhD thesis 
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Cardiovascular follow-up of paediatric Turner patients 
In the Ghent University Hospital, paediatric TS patients are seen regularly at the Paediatric 
Cardiology Department. The frequency of the check-ups depends on the presence or absence of a 
CHD or aortic dilation (figure 12). All patients are evaluated by an experienced paediatric 
cardiologist at the time of diagnosis. If no CHD or aortic dilation (diameter of the aortic root and 
diameter of the ascending aorta with z-score <2) is present at that time, patients are examined 
approximately once every 5 years: at the start of growth hormone treatment (or at the age of 7 
years), at the start of puberty induction (or at the age of 13 years in case of spontaneous menarche) 
and before transition to the adult cardiology department. If the patient has a CHD or a dilated 
ascending aorta, cardiovascular follow-up is organised on a yearly basis or more frequently if 
appropriate. Paediatric TS patients with a BAV without aortic dilation are seen every 2 years. 
A cardiovascular check-up consists minimally of an ECG, in office blood pressure measurement at 
the 4 limbs and a complete ultrasound examination with measurement of the aortic diameters. 
Based on the results of this PhD research, we recently added the measurement of aortic wall 
stiffness using M-mode. A 24h blood pressure recording is routinely planned once before puberty 
induction and before transition, but is also performed electively in patients with in office 
hypertension, coarctation or important aortic dilation. Even if the ultrasound is normal, a cardiac MRI 
is performed before transition for the evaluation of aortic diameters, aortic arch morphology and 
PWV. 
 
Cardiovascular follow-up of adult Turner patients 
Adult TS patients are evaluated regularly by an adult cardiologist experienced in TS and adult CHD 
(figure 13). Basically, the follow-up of adult TS patients does not differ from that of children and 
includes an ECG, blood pressure measurement at the 4 limbs and cardiovascular imaging by 
ultrasound and MRI. Recently we added MRI derived PWV of the aorta to the follow-up protocol. 
Patients without CHD or aortic dilation (aortic diameter <20 mm/m²) have a complete cardiovascular 
check-up every 3 to 5 years. Patients with a BAV are evaluated every 1 to 2 years depending on the 
valvular function and the association with aortic dilation. If the TS patient has a dilated aorta or a 
CHD, the cardiovascular assessments are more frequent with a minimum of once a year. A cardiac 
MRI is performed at least every 5 years, but the frequency is increased in TS patients with important 
aortic dilation and/or an associated CHD. 
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Figure 13: flowchart for the follow-up of TS patients. 
Adaptations of the protocol based on the insight of the PhD research are marked in 
italic. 
Congenital heart defect includes congenital CHD and isolated dilation of the ascending 
aorta (Z-score ≥2 for children and ASI ≥20 mm/m² for adults) 
 
Cardiovascular follow-up of pregnant TS patients 
An elaborated cardiovascular screening is necessary prior to conception for all TS patients who 
want to conceive either spontaneous or via oocyte donation. This work-up includes a complete 
ultrasound exam with measurement of the aortic diameters, a cardiac MRI and 24h blood pressure 
measurement. As pregnancy increases the risk for aortic dilation, repeated echocardiography with 
measurement of the aortic dimensions is performed in the first, second and third trimester and in the 
postpartum period. Pregnancy is discouraged in TS patients with coarctation, previous cardiac 
surgery, aortic dilation ≥25 mm/m² or uncontrolled hypertension [9, 17]. 
 
Cardiovascular follow-up of male patients with mosaic 45,X/46,XY 
Until recently, males with 45,X/46,XY were not referred for cardiovascular screening. Based on the 
results of the first publication (III.1), these patients are now treated similar to females with TS (figure 
13).  
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IV.6 Challenges and limitations of the research papers 
Challenge of studying a rare disease 
Turner syndrome is a rare disease occurring in approximately 1/2000 to 1/5000 live born girls. 
Based on these reported incidences and the number of women aged 0-60 years in Flanders (2008, 
Stat.be), the number of TS patients in Flanders is roughly estimated at 400 to 1040. For the 
paediatric population under the age of 15, the estimated number of TS varies between 100 and 250. 
These low numbers of TS patients inevitably lead to small study populations. 
In the first paper (III.1) we selectively included TS patients with 45,X/46,XY, a rare mosaic form 
found in only 6% of TS patients and compared them with another rare group of males with 
45,X/46,XY. At the time of the study, the Belgian Registry for Growth and Puberty problems 
contained 34 patients with a mosaic 45,X/46,XY (24 females and 10 males) followed in 7 university 
hospitals. Although we did major efforts to include them all in the study, only 11 could be enrolled 
(32%). Two centres were not interested to participate (respectively 2 and 6 patients), 4 patients 
were lost to follow-up, 10 patients refused to participate and 1 male patient deceased suddenly at 
the age of 24 years. Seven additional patients were included via the multidisciplinary clinic for 
disorders of sexual development (DSD) of the Ghent University Hospital. Recruitment via the 
Belgian Registry for Growth and Puberty Problems and a university DSD outpatient clinic could 
cause a selection bias towards short boys and/or boys born with ambiguous genitalia and does not 
include asymptomatic 45,X/46,XY males who might have a milder cardiovascular phenotype. Future 
research should include asymptomatic males with 45,X/46,XY who present at the fertility clinic but 
due to the privacy legislation it is very difficult to reach this specific population. 
The second paper (III.2) retrospectively reviewed the MRI of 74 adult TS patients. Although the 
absolute number is relatively low, it accounts for 80% (74/92) of the total number of adult TS 
patients followed in Ghent University Hospital. A similar remark can be formulated for the fourth 
paper (III.3.2). International multicenter studies are needed to increase the study population but 
these large studies require a different management with elaborated funding and administrative staff. 
In the third paper (III.3.1) all 15 prepubertal TS girls followed at the Ghent University Hospital were 
included. As Turner syndrome is frequently diagnosed during adolescence or even adulthood, these 
patients probably represent less than 50% of all prepubertal TS girls. This could possibly have 
caused a bias towards the more severe phenotypes. 
 
Possible bias of studying a syndrome with a variety of genotypes and phenotypes 
The genotype of TS patients is very heterogeneous and includes patients with monosomy 45,X, with 
isochromosome 46,X,i(X), deletion 46,X,del (X) or a variety of mosaic forms. Although CHD and 
aortic dilation are more prevalent in TS patients with monosomy 45,X, there is no clear correlation 
between the genotype and the cardiac phenotype. The genes responsible for the different 
cardiovascular anomalies remain currently unknown. 
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Apart from the first paper that only included patients with 45,X/46,XY, the other publications 
describe TS patients with various karyotypes. The limited number of the patients did not allow 
investigating the relation between karyotype and the prevalence and severity of aortic arch 
abnormality (III.2) or aortic wall stiffness (III.3.1 and III.3.2).The second paper (III.2) was a 
retrospective analysis including patients that were recently transferred to our Ghent University 
Hospital. In some medical files, the original genetic result was lacking making it impossible to 
classify the patient in a certain genotype group. 
The phenotype of TS patients is highly variable; some patients remain undiagnosed until adulthood 
while others are not unrecognized at all. We can therefore not rule out that the TS populations we 
studied represent the most severe phenotypes and may therefore be biased toward a more affected 
group. 
 
Difficulty of choosing an adequate control group 
The third paper (III.3.1) included healthy prepubertal girls as controls for the TS group. As TS girls 
have a small stature, we decided to match not only for sex and age but also for height; we only 
included girls with a height below the 25
th
 percentile. Although none of our TS patients was obese, 
they tend to have a higher weight compared to their small height. In contrast, constitutional small 
girls tend to have low weights. As a consequence, there was a significant difference in BMI between 
the 2 groups. We cannot rule out a possible bias of this different constitution on aortic wall elastic 
properties. 
In the fourth paper (III.3.2) the control group consisted of a historical cohort. On average, control 
patients were taller and weighed more than TS patients while their BMI was slightly lower. The 
mean age of the control group was 10 years older than the TS group. This considerable difference 
may not have been completely overcome through statistical modelling. However, finding a stiffer 
aorta in the TS group that is 10 years younger than the control group probably adds power to the 
conclusion that an abnormally stiffer aorta presents at an early age. 
 
Possible bias of drug use in a group of patients who require chronic medical treatment 
The most distinctive features of TS are small stature and premature ovarian failure. The first is 
treated by administering supraphysiologic doses of growth hormone, the latter by hormone 
replacement therapy. From an ethical point of view it is very difficult to stop one of these treatments 
for a longer period just for the purpose of research 
In the fourth paper (III.3.1) the possible role of estrogen replacement was countered by studying 
prepubertal TS girls. However, we could not rule out a bias of GH, as 12 of the 15 patients were on 
GH treatment. 
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In the second (III.2) and fourth (III.3.2) publication, we retrospectively checked the medical files of 
the TS patients for the duration and dosage of GH and estrogen therapy. There were too many 
missing data to study the effect of GH or HRT on aortic arch morphology and blood pressure or 
aortic dilation and aortic stiffness. 
 
Unknown contribution of other risk factors 
TS patients can present a variety of pathology like diabetes, thyroid dysfunction, dyslipidemia and 
renal dysfunction. All these disorders can have a detrimental influence on the cardiovascular health 
status of TS patients. 
In the third publication (III.3.1) none of the very young TS patients had comorbidity or chronic drug 
use apart from GH treatment. The study protocols in adult TS patients did not intend to study the 
impact of dyslipidemia, thyroid function, renal function, smoking habits and physical activity on aortic 
arch morphology, aortic dilation or aortic stiffness. These data were therefore not included in the 
analysis, but a possible bias cannot be ruled out. 
 
Limitations of non-invasive clinical research 
Animal models of TS are lacking and research on the cardiovascular pathology in this syndrome is 
limited to clinical research in human TS patients. 
Studies in children predominantly use non-invasive methods that create minimal discomfort or pain. 
MRI imaging was therefore not considered in the third paper (III.3.1) as it is time consuming and 
requires the administration of IV contrast fluid. Ultrasound on the other hand is well tolerated and is 
performed in a relatively short time interval. Although visualisation can be difficult in adult TS 
patients, the quality of the images in our study population was adequate for measuring all 
parameters; M-mode based calculation of distensibility and stiffness was possible in all participants. 
Due to the limitations of the technique, it was impossible to measure parameters of stiffness of the 
distal aorta. Ultrasound derived PWV showed to be inadequate in TS patients. 
Calculation of distensibility and stiffness index requires systolic and diastolic blood pressure values. 
In the clinical research protocols (III.3.1 and III.3.2), the blood pressure was measured non-
invasively at the arm which might not be representative for the central pressure that is needed. 
Theoretically, the abnormal aortic wall properties of TS patients can lead to an increased 
transmission velocity of both forward and reflected waves, which causes the reflected wave to arrive 
earlier in the central aorta and increases the central pressure in systole. To evaluate a possible 
impact of blood pressure bias, distensibility and stiffness index of prepubertal TS girls were 
recalculated with blood pressure values that were increased with 10%. Distensibility increased and 
stiffness index decreased, but the difference between TS and controls remained statistically 
significant. 
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Blood pressure measurement in Turner patients 
Taken into account that TS patients often have an abnormal arch morphology, measuring the blood 
pressure at the left arm can theoretically underestimate the real blood pressure. Moreover, in office 
blood pressure measurement can lead to underdiagnosis of arterial hypertension in TS as nocturnal 
hypertension and abnormal dipping are frequently seen in these patients. Additionally, the definition 
of hypertension has slightly changed over time and the definition of hypertension was not the same 
in the different study protocols. 
In the first paper (III.1) blood pressure was measured in office at both arms. Hypertension was 
defined as a blood pressure above the 95
th
 percentile in children and above 130/85 mmHg in adults. 
We could not conclude on the prevalence of nocturnal hypertension or abnormal nocturnal dipping 
in 45,X/46,XY patients. 
In the second paper (III.2) blood pressure values were recorded from the medical files. In many 
cases, the side of the blood pressure measurement was not recorded. Ambulatory blood pressure 
measurement was only available in 22 cases. Patients were considered hypertensive if the in office 
blood pressure exceeded 140/90 mmHg, if the mean ambulatory blood pressure exceeded 130/80 
mmHg or if they were treated with antihypertensive drugs. Although this stratification reflects clinical 
practice, it might have under- or overestimated the number of hypertensive TS patients. 
In the third paper (III.3.1), we used the in office blood pressure values at the right arm for the 
calculation of distensibility and stiffness index to avoid interference of aortic arch morphology on the 
blood pressure measurements. Additionally, blood pressure was measured in office at the 4 limbs. 
The post hoc analysis, could not detect a significant difference (or a trend) in the blood pressure 
values between the left and right arm in TS patients. Twenty-four hour recording was only available 
in 11 girls, not enough to study the relation between mean blood pressure or abnormal nocturnal 
dipping and aortic wall elastic properties. 
In the fourth paper (III.3.2) blood pressure was taken at the left arm during the MRI exam. Yet 
again, the sensitivity analyses in study III.3.1 and III.3.2 showed conclusions on distensibility and 
stiffness index to be robust for 10% increase or decrease in the blood pressure measurements in 
TS patients. 
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IV.7 Future research 
This PhD research added information on the aetiology of aortic dilation in Turner syndrome but 
several highways and sidetracks still remain to be explored. Future research on the pathogenesis of 
aortic dilation and dissection in TS should therefore try to unravel the complex connection between 
abnormal aortic stiffness, aortic dilation and associated risk factors. 
 
Additional information could be gathered by: 
 comparing aortic dimension and aortic wall distensibility in non-syndromic patients with BAV and 
Turner patients to clarify the relative contribution of the intrinsic aortic wall property and the add-
on effect of BAV in TS; 
 following aortic arch morphology in time to determine whether abnormal arch morphology is 
present from birth or develops progressively later in life; 
 measuring aortic distensibility repetitively to understand the role of aortic stiffness in the 
development of aortic dilation, aortic arch deformation and hypertension; 
 measuring aortic distensibility and aortic diameters repetitively to clarify the relative role of both 
parameters in the evolution toward dilation and dissection; 
 developing experimental flow models that could help to study flow alterations in stiff aortic 
arches and the association of abnormal flow with aortic arch deformation and head vessel 
dilation; 
 measuring aortic stiffness parameters in males and females with 45,X/46,XY to clarify if the 
abnormal aortic stiffness is linked to the X chromosome haploinsufficiency; 
 following males with 45,X/46,XY over time to clarify if those with a tricuspid aortic valve are also 
at risk for aortic dilation; 
 studying the relationship between the Turner karyotype and the presence of CHD, the presence 
of abnormal aortic stiffness and the severity of aortic dilation; 
 studying the relationship between the prenatal nuchal translucency and the presence of CHD, 
the presence of abnormal aortic stiffness and the severity of aortic dilation. This will probably 
only be possible for the paediatric population, as it will be very difficult to gather the data on 
nuchal translucency retrospectively; 
 studying the relationship between the presence of dysmorphic features (including webbed neck) 
and the presence of CHD, the presence of abnormal aortic stiffness and the severity of aortic 
dilation; 
 studying the usefulness of betablockers and losartan in the prevention of accelerated aortic 
growth; 
 cooperating in international research on the histological nature of the aortic wall of TS patients. 
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IV.8 General conclusion of the PhD thesis: abnormal aortic stiffness, the 
missing link for aortic dilation and dissection 
Aortic dissection is a major issue in Turner syndrome as it is associated with an increased risk for 
morbidity and mortality. Aortic dilation and CHD play a major role in the progression to this often 
lethal complication. Current guidelines advocate regular cardiovascular follow-up that include the 
evaluation of traditional risk factors like blood pressure, aortic dimensions, the presence of a 
bicuspid aortic valve and coarctation or ETA. They however seemed insufficient to explain all cases 
of aortic dissection. 
 
Our data suggest that an intrinsic genetically determined increased aortic wall stiffness cooperates 
with and modulates the other well known risk factors for aortic dilation. We propose to add it as “the 
missing link” in the risk stratification for aortic dilation and dissection in Turner syndrome and to 
include it in the regular follow-up of TS patients. 
  















V.1 Summary of the PhD thesis (in English) 
Turner syndrome is a chromosomal disorder occurring in 1/2000 to 1/5000 live born girls. 
Cardiovascular pathology is common in TS patients and includes structural (left sided) 
cardiovascular defects, hypertension, ECG alterations and aortic dilation and dissection. Morbidity 
and mortality are increased compared to the general population, aortic dissection being the most 
important cause of early demise. The presence of a bicuspid aortic valve, coarctation and 
hypertension – all highly prevalent in TS – increases the risk for aortic dilation and dissection but 
this often lethal complication also presents in TS patients without one of these classical risk factors. 
In this thesis, additional information on the pathogenesis of aortic dilation in TS was sought. 
Cardiovascular pathology in TS is probably related to the genetic haploinsufficiency of the X 
chromosome. We found cardiac pathology that is typically associated with TS pathology (bicuspid 
aortic valves, aortic dilation and ECG alterations) in males with mosaic 45,X/46,XY (one of the TS 
genotypes). In those male 45,X/46,XY patients, cardiovascular pathology was more frequent in 
those who also had other TS related abnormalities. Based on this findings cardiac screening and 
lifetime monitoring in all males with 45,X/46,XY mosaicism according to the existing guidelines for 
Turner syndrome is advised. 
Besides aortic dilation, elongation of the aortic arch is a common finding in TS. Our study showed 
that abnormal arch morphology is present in nearly 40% of TS patients and can also be seen in 
patients without associated coarctation or abnormal aortic valve. A significant association was found 
between abnormal arch morphology and hypertension in TS patients. Patients with an abnormal 
arch morphology more often had a dilation of the ascending aorta, suggesting that abnormal arch 
morphology might be an additional risk factor in the risk stratification for aortic dilation and 
dissection. 
We found that TS patients with a bicuspid or tricuspid aortic valve have an increased stiffness of the 
ascending aorta from a young age on although this abnormality is more pronounced in TS patients 
with a BAV. In young TS girls severe dilation of the ascending aorta was only found in patients with 
a bicuspid aortic valve. In adult TS patients aortic dilation was found in patients with a bicuspid or a 
tricuspid valve although the dilation was more pronounced in those with a bicuspid valve. We 
concluded that Turner patients exhibit a predominant stiffening and dilation of the proximal aorta, 
especially if their aortic valve is bicuspid. These abnormalities are present from an early age, 
suggesting an intrinsic wall pathology inherent to the TS syndrome. 
 
Our data suggest that an intrinsic genetically determined increased aortic wall stiffness cooperates 
with and modulates the other well known risk factors for aortic dilation. We propose to add it as “the 
missing link” in the risk stratification for aortic dilation and dissection in Turner syndrome and to 




V.2 Samenvatting van de doctoraatsthesis (in het Nederlands) 
Turner syndroom (TS) is een zeldzame genetische aandoening die optreedt in 1/2000 tot 1/5000 
levend geboren meisjes. Ze wordt gekenmerkt door het verlies van een gedeelte of van heel het X-
chromosoom. Vele Turner patiënten lijden aan hart- en vaatziekten waarbij structurele 
hartafwijkingen, hoge bloeddruk, ECG afwijkingen, dilatatie (abnormale uitzetting) en dissectie 
(ontstaan van scheurtjes in de vaatwand) van de aorta worden beschreven. In vergelijking met “de 
algemene bevolking” is de morbiditeit en mortaliteit in patiënten met TS sterk toegenomen. Vooral 
dissectie van de aorta, die kan optreden op zeer jonge leeftijd, speelt hierin een belangrijke rol. 
Bicuspide aortaklep (aortaklep met 2 ipv 3 klepblaadjes), coarctatio (vernauwing thv de grote 
lichaamsslagader) en hypertensie (hoge bloeddruk) komen vaak voor bij TS patiënten en zijn 
gekende risicofactoren voor het ontwikkelen van aortadilatatie en dissectie. Er zijn in de literatuur 
echter ook patiënten met aortadissectie beschreven die niet één van deze gekende klassieke 
risicofactoren vertoonden. In dit thesisonderzoek werd gezocht naar bijkomende informatie over het 
ontstaan van aortadilatatie in TS. 
Vermoedelijk ligt haplo-insufficiëntie van het X-chromosoom aan de basis van de hart- en 
vaatziekten in TS patiënten. Mozaïek 45,X/46,XY is één van de gekende genotypes die het TS 
veroorzaken. Het wordt ook teruggevonden bij mannelijke patiënten met gonadale dysgenese. In de 
eerste publicatie wordt beschreven dat typische Turner gerelateerde hartafwijkingen zoals bicuspide 
aortaklep, aortadilatatie en ECG afwijkingen ook bij mannen met mozaïek 45,X/46,XY worden 
teruggevonden. Cardiovasculaire afwijkingen werden het vaakst gevonden bij mannelijke patiënten 
die ook andere typische Turner kenmerken vertonen. Op basis van deze bevinding adviseren wij 
om levenslange cardiovasculaire opvolging te voorzien bij alle patiënten met 45,X/46,XY, ook bij 
diegenen met een mannelijk fenotype. 
De tweede publicatie beschrijft een retrospectieve MRI studie bij volwassen vrouwen met TS waarin 
wordt aangetoond dat 40% van de TS patiënten een abnormale aortaboogmorfologie vertoont. 
Deze wordt ook gevonden bij TS vrouwen zonder coarctatio of abnormale aortaklepmorfologie. We 
vonden een significante associatie tussen de aanwezigheid van een abnormaal gehaakte boog en 
hypertensie. Patiënten met een abnormale boogmorfologie hadden ook vaker een gedilateerde 
aorta ascendens. Dit suggereert dat een abnormale boogmorfologie een bijkomende risicofactor 
zou kunnen vormen voor het ontstaan van aorta dilatatie en mogelijk dissectie. 
In een prospectieve studie vergeleken we de elasticiteit van de aorta van patiënten met TS met die 
van normale controles. Bij patiënten met TS vonden we een abnormaal stijvere aorta ascendens, 
zowel bij diegenen met een bicuspide als diegenen met een tricuspide aortaklep. Het verschil was 
echter meer uitgesproken bij TS patiënten met een bicuspide aortaklep. In jonge prepuberale 
Turner meisjes vonden we enkel een significante dilatatie van de aorta ascendens bij diegenen met 
een bicuspide aortaklep terwijl dilatatie van de aorta ascendens bij volwassen patiënten significant 
groter was bij patiënten met een bicuspide aortaklep in vergelijking met diegenen met een tricuspide 
aortaklep. Uit deze resultaten besloten we dat TS patiënten een abnormale stijfheid vertonen van 
de aorta ascendens, die nog meer uitgesproken is in de aanwezigheid van een bicuspide aortaklep. 
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Deze afwijking is reeds op jonge leeftijd terug te vinden wat suggereert dat het om een intrinsiek 
probleem gaat met slechts een beperkt effect van versnelde veroudering. 
 
Onze data suggereren dat het Turner syndroom gekenmerkt wordt door een abnormale stijfheid van 
de aorta die intrinsiek genetisch is bepaald en die andere goedgekende risicofactoren van 
aortadilatatie moduleert en versterkt. We stellen dan ook voor om abnormale vaatstijfheid van de 
aorta toe te voegen als “missing link” in de risicostratificatie voor aortadilatatie en dissectie in TS en 
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De titel van deze PhD thesis bevat niet toevallig het woord “queste”. Het verwoordt exact wat dit 
onderzoeksproject voor mij betekend heeft: een queeste, een zoektocht in al zijn letterlijke en 
figuurlijke betekenissen. 
Het is een zoektocht geweest naar wetenschappelijke kennis in de hoop daarmee een bijdrage te 
leveren aan een betere zorg voor onze patiënten. Een streven ook naar persoonlijk erkenning in de 
academische wereld en in het eigen ziekenhuis. Tijdens deze zoektocht naar waarheid en kennis is 
er één persoon die ik ongevraagd steeds weer opnieuw tegenkwam: mezelf. Soms was het een 
verrassend aangename ontmoeting waar kracht uit werd geput, andere confrontaties waren minder 
luisterrijk. Een persoonlijkheidstest en een karaktertraining is het zeker geweest… 
Het was een lange tocht, die bijna 8 jaar heeft geduurd. Net zoals bij elke queeste was ook mijn 
traject onvoorspelbaar en grillig. Ik trotseerde hoge bergen en diepe donkere dalen. Er zijn zijpaden 
geweest waarop ik onverrichter zake moest omkeren en die veel kostbare tijd en energie hebben 
gekost. Hier en daar waren er verraderlijke putten waar de tocht vertraagde; er was veel creativiteit 
en volharding nodig om deze obstakels te overwinnen. Gelukkig waren er ook mooie groene vlaktes 
waar de tocht lekker opschoot en waar mooie resultaten werden geboekt.  
Een queeste zou geen queeste zijn als ze niet gepaard ging met wonderbaarlijke ontmoetingen. Ik 
ben op mijn tocht ontelbare mensen tegengekomen die kortdurend mijn pad hebben gekruist. 
Anderen hebben grote stukken van de weg met me meegelopen en enkelen hebben zelfs het ganse 
traject samen met mij afgelegd. Alhoewel ik niet iedereen met naam kan noemen, ben ik al die 
mensen oneindig dankbaar. 
Toch wil ik enkele personen specifiek bedanken. Mijn promotor, prof. dr. Daniël De Wolf en mijn 
tweede promotor prof.dr. Jean De Schepper hebben de aanzet gegeven voor dit grote avontuur. Ze 
hebben me hun vertrouwen geschonken om zelf mijn pad te banen en de queeste te voltooien op 
de manier die ikzelf goed achtte. Bedankt voor deze mogelijkheid, Daniël en Jean. Ik ben blij dat ik 
het einde van dit avontuur zonder al te veel kleerscheuren heb gehaald. Dank ook, Daniël, voor het 
vertrouwen dat u al jaren in me stelt. U hebt ons kindercardiologische team uitgebouwd tot een 
stevige kern waarin ik op mijn eigen manier mijn eigen plaats mag innemen. Bedankt voor dat 
vertrouwen! 
Ook mijn oprechte dank aan de leden van de examenjury voor hun eerlijke mening en opbouwende 
kritiek bij het lezen van “mijn verhaal”: prof François, prof. Callewaert, prof. Deneyer, prof. 
Gheeraert, prof. Matthys, prof. Suys en prof. T’Sjoen. Met de hulp van jullie suggesties is het 
eindresultaat geworden wat het nu is: een thesis waar ik heimelijk toch een beetje trots op ben. 
Ook prof Vandewalle, voorzitter van de examcommissie, ben ik grote dank verschuldigd voor zijn 
niet aflatende aanmoedigingen en tips bij praktische PhD-vragen. Van harte dank daarvoor, Johan!  
Een hele speciale en hele oprechte “dank u wel” wil zeggen aan prof. Dirk Matthys. U gaf me bijna 
15 jaar geleden de mogelijkheid om vanuit Antwerpen naar Gent te komen en om me te 
specialiseren in de mooiste subdiscipline die er bestaat: de kindercardiologie. Met uw hulp ben ik 
ondertussen ook een vast lid van de grote en mooie familie die “pediatrie” heet. U bent ook diegene 
die me 2 jaar geleden aanmaande om er wat vaart achter te zetten. U wilde me graag zien 
promoveren voor uw emeritaat. Het is me net gelukt… Dank ook aan U en Dora voor de gastvrijheid 
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die u me verleende aan het begin van mijn carrière als supervisor. Er zijn niet veel mensen die 
kunnen zeggen dat ze bij hun grote baas mochten logeren tijdens hun wachtdienst. 
De aandachtige lezer heeft vermoedelijk opgemerkt dat er nog enkele andere namen herhaaldelijk 
opduiken in dit verhaal.  
Dr. Dan De Vos, zonder jouw gedrevenheid en medewerking was deze PhD-thesis niet mogelijk 
geweest. Alle MRI beelden die ik gebruikte zijn van jouw hand. Bedankt voor de vele mooie 
illustraties die je me bezorgde en voor de interessante discussies die we voerden bij de interpretatie 
van de gegevens. 
Dr. Laurent Demulier, “Turner-dokter” op de volwassen cardiologie”. Bedankt voor je kritische 
opmerkingen die de vele overlegmomenten tot een grote meerwaarde maakten. Met jouw 
empathisch vermogen zijn onze volwassen vrouwen met Turner syndroom in de beste handen. 
Dank ook aan prof. dr. Julie De Backer en prof. dr. Tine De Backer, twee vrouwen die het gemaakt 
hebben in de onderzoekswereld en waar ik veel bewondering voor heb. Ondanks jullie zeer drukke 
bezigheden kon ik steeds een beroep op jullie expertise. 
Prof. dr. Martine Cools, u wijdde me in in de mysterieuze wereld van de DSD. Uw inzichten waren 
onontbeerlijk in de interpretatie van de eerste studieresultaten. 
Prof. dr. Rita Craen, uw enthousiasme overtuigde me om me te verdiepen in de cardiovasculaire 
problemen van Turner patiënten. U gaf me ook de suggestie om ook eens te kijken naar mannen 
met 45,X/46,XY. Het was het allereerste startschot voor het verdere PhD-onderzoek. 
Een woord van dank ook aan alle andere leden van de Turner Kliniek: er is in Gent, mede door jullie 
gedrevenheid, een uniek multidisciplinair team uitgebouwd. Vanuit heel België vinden patiënten de 
weg naar ons centrum en de populatie Turner patiënten die door ons wordt gevolgd is enorm 
toegenomen. Enkel op deze manier wordt klinisch onderzoek mogelijk. Dank dus, voor al jullie 
goede zorgen en extra inspanningen voor “onze” Turner patiënten. Hopelijk ziet ook onze directie 
de mogelijkheden die deze kliniek ons biedt en is ze bereid om haar financiële duit in het zakje te 
doen. 
Klinisch onderzoek is enkel mogelijk met de onbaatzuchtige medewerking van patiënten en hun 
familie. Mijn oprechte dank aan allen die bereid waren om voor mijn onderzoek naar het UZ Gent te 
komen, zeer speciaal ook alle “controle meisjes en hun ouders” die voor mij een uurtje van hun vrije 
tijd opofferden. Dank aan alle collegae kinderendocrinologen die hun patiënten motiveerden om 
deel te nemen aan de studieprotocollen: prof. dr. Jean De Schepper, prof. dr. Rita Craen, prof. dr. 
Martine Cools, dr. Kathleen De Waele, dr. Sara Van Aken, dr. Saskia Van der Straaten voor het UZ 
Gent en dr. Inge François voor de KU Leuven. 
Een bijzondere woord van dank ook aan de Stichting ter Bevordering van het Onderzoek in 
Kindercardiologie dat Belgisch multicenter onderzoek niet enkel aanmoedigt maar ook financieel 
ondersteunt. Dank aan prof dr. Marc Gewillig (KU Leuven) en prof. dr. Thierry Sluysmans (UCL) 
voor de inclusie van hun patiënten in de eerste studie.  
En dan zijn er de vele supporters langs de weg. Zonder jullie aanmoedigingen, steun en praktische 
hulp was de eindmeet vermoedelijk nooit bereikt. 
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Eerst en vooral “mijn mannen”, zoals ik ze graag noem: dr. Kristof Vandekerckhove, dr. Seppie 
Panzer, dr. Hans De Wilde en dr. Mahmoud Zaqout. Jullie waren van zeer nabij getuige van mijn 
soms moeizame tocht. Ik kon met mijn frustraties steeds bij jullie terecht en in de laatste fase 
maakten jullie het mogelijk om me terug te trekken in mijn cocon om mijn wedervaren op een rustige 
manier uit te schrijven. Dikke, dikke merci! Ik hoop voor jullie binnenkort hetzelfde te kunnen doen. 
Chris Leyman, onze vaste kindercardio-verpleegkundige. In mijn beginperiode was je vaak mijn rots 
in de cardiologiebranding en het aantal ECG’s en bloeddrukken die je voor mijn studies nam zijn 
ondertussen niet meer te tellen. Bedankt, ik zal je heel erg missen, volgend jaar… 
En dan de vrouwen van de dienst: Ilse Coomans en Christelle Maes, vanaf het prille begin waren 
jullie “mijn zusters in het kindercardiologische mannen-bastiljon”. Steeds bereid tot een babbeltje, 
steeds bereid tot hulp! Mijn dank voor jullie steun op alle vlakken is niet in woorden uit te drukken. 
Bedankt ook aan alle andere secretaresses die de laatste jaren onze dienst kwamen versterken en 
die een onmisbare hulp zijn in onze dagelijkse werking. 
En dan zijn er de ontelbare andere mensen die het dagelijkse werk in het UZ Gent aangenaam 
maken en die me aanmoedigden op momenten dat het pad onbegaanbaar leek. Ik kom op erg veel 
verschillende diensten en het zijn er dus veel te veel om persoonlijk op te noemen: mijn collegae 
kinderartsen, cardiologen, chirurgen, artsen en vroedvrouwen op de prenatale diagnostiek, 
psychologen, ontelbare verpleegkundigen en logistieke medewerkers, sociale assistenten, 
secretaresses, … Aan iedereen: bedankt voor wie jullie zijn en wat jullie dagelijks presteren! 
En dan uiteindelijk het thuisfront, zij die het meest geleden hebben onder mijn lange mentale 
afwezigheid. Mama en papa, bedankt voor de fijne en warme thuis waarin ik mocht opgroeien. 
Bedankt voor het vertrouwen dat ik kreeg en alle mogelijkheden die jullie me geboden hebben. 
Bedankt ook mama, voor het mooie ontwerp dat de cover van dit PhD-werk tot een persoonlijk 
kunstwerk maakt. Dank ook aan mijn schoonouders, broer, schoonzussen en schoonbroers voor 
hun morele steun tijdens de lange tocht. 
Morgane en Jules, mijn twee grootste schatten. Het is een lange tocht geweest, ook voor jullie. Bij 
de start van het verhaal Jules was nog een schattige kleuter en Morgane een vrolijk klein meisje in 
het tweede leerjaar. Onderweg zijn jullie uitgegroeid tot 2 grote knappe tieners. Jullie hebben de 
laatste 2 jaren niet zo veel aan jullie mama gehad. Het was ofwel werken in het ziekenhuis, ofwel 
werken thuis. De verloren tijd kan ik niet meer terugbrengen, maar ik beloof wel dat ik er vanaf nu 
vaker “echt zal zijn” voor jullie. 
En dan, last but not least: Koen. Bij het dankwoord aan het einde van een verdediging wordt de 
echtgenoot traditioneel als laatste bedankt, meestal voor zijn inbreng in het huishouden en de zorg 
voor de kinderen. Dat ga ik nu niet doen … Jouw rol in dit werk was zoveel meer dan dat. Jij bent in 
dit verhaal mijn Gandalf: mijn persoonlijke huisprofessor, aanwezig van begin tot einde en nu en 
dan opduikend met een bijna magische oplossing. Je was bij elke fase van het onderzoek 
betrokken: bij het begin van een project als we samen de methodologie bespraken, bij de 
verwerking als de statistiek weer eens (te) moeilijk was, bij het nalezen van de artikels… Jouw 
expertise als onderzoeker heb ik steeds mogen (mis)bruiken. Ook in de eindfase was jouw inbreng 
onbetaalbaar bij de layout van het drukwerk, commentaar op de dia’s, kiezen van een outfit… En nu 
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is dit hoofdstuk van ons verhaal ten einde. Eindelijk! Ik zou je willen beloven dat er vanaf nu meer 
tijd vrijkomt voor ons twee, maar dat zal niet alleen aan mij liggen. 
Bedankt, Koen. Zonder jou was dit niet verhaal nooit geschreven. 
  
 
